

## Sunday, 15. June 2025

### Pre-Congress Course

09:00 - 15:00

PCR1

#### **CINP Research Fellowships 2025 Colloquium (By Invitation Only)**

Chair: Matthew Kang (Melbourne, Australia)

Chair: Shyh-Yuh Wei (Tainan, Taiwan)

##### **Get Together**

09:00 - 09:15

##### **Welcome and Introductions**

09:15 - 09:30

Speaker: Matthew Kang (Melbourne, Australia)

Speaker: Shyh-Yuh Wei (Tainan, Taiwan)

##### **Multiple facets of research in Alcohol Use Disorder (AUD)**

09:30 - 10:10

Speaker: Ming-Chyi Huang (Taipei, Taiwan)

##### **Importance of Preclinical Research & Yes of BioCommons/Data Science to Link Preclinical and Clinical Research**

10:10 - 10:40

Speaker: Rachel Hill (Clayton, Australia)

##### **Discussion & Coffee Break**

10:40 - 11:10

##### **Fellowship Project Plan Discussion and Refinement**

11:10 - 12:30

Speaker: Ming-Chyi Huang (Taipei, Taiwan)

Speaker: Rachel Hill (Clayton, Australia)

Speaker: Matthew Kang (Melbourne, Australia)

Speaker: Shyh-Yuh Wei (Tainan, Taiwan)

##### **Discussion & Lunch**

12:30 - 13:30

### Session

14:00 - 15:00

PCR2

#### **Innovative Perspectives in Neuropsychopharmacology: Insights from Indonesia and Australia**

Chair: Yuki Moriya (Tokyo, Japan)

##### **Effect of Fluoxetine to Progressivity of Intervertebral Disc Disorder of Patients with Psychiatric Comorbidity in Maria Walanda Maramis District General Hospital of North Minahasa, Indonesia**

14:00 - 14:15

Speaker: Ireine Suantika Cornelia Roosdy (Manado, Indonesia)

##### **Innovative perspectives in neuropsychopharmacology: insights from Indonesia, NewZealand and Australia**

14:15 - 14:30

Speaker: Suzy Yusna Dewi (Jakarta, Indonesia)

##### **Comparison of features of relapse risk between alcohol-dependent individuals in Japan and Australia through use of validated self-rating scale: the Alcohol Relapse Risk Scale**

14:30 - 14:45

Speaker: Shijia Winson Lu (Sydney, Australia)

##### **Experiences with Nitazene Withdrawal**

14:45 - 15:00

### Session

15:15 - 16:30

PCR2

#### **Cutting-Edge Clinical and Basic Research on Mental Disorders: Perspectives from Indonesian Psychiatry Experts**

Chair: Andi Tanra (Makassar, Indonesia)

##### **Adoption of Japanese Spiritual and Religious Approaches for Disaster Recovery and Awareness in Indonesia**

15:15 - 15:30

Speaker: Era Catur Prasetya (East Java, Indonesia)

##### **Unmet needs of abandoned older adults with mental disorders in Institutional Care**

<i>Speaker:</i> Arundhati Nugrahaning Aji (Jakarta, Indonesia)	15:30 - 15:45
<b>The Role of SSRIs in Improving Cognitive Impairment in an Adolescent with Trauma: A Case Study in Indonesia</b>	15:45 - 16:00
<i>Speaker:</i> Frilya Rachma Putri (Malang East Java, Indonesia)	
<b>Alpha Brain Wave Stimulation in Reducing Depression in Chronic Pain</b>	16:00 - 16:15
<i>Speaker:</i> Santi Yuliani (Magelang, Indonesia)	
<b>Community Health Empowerment for Early-Detecting and Reintegrating of Schizophrenia in Indonesia</b>	16:15 - 16:30
<i>Speaker:</i> Citra Fitri Agustina (Jakarta Pusat, Indonesia)	
 <i>Networking</i> 15:45 - 16:45	SR
<b>Early Career Welcome Reception</b>	
 <i>Plenary</i> 17:00 - 18:00	PL
<b>Opening &amp; Awards Ceremony</b>	
 <i>Plenary</i> 18:00 - 19:00	PL
<b>Plenary 1: Keynote Lecture Guy Goodwin</b>	
<i>Chair:</i> Hiroyuki Uchida (Japan)	
<i>Chair:</i> Tung-Ping Su (Taipei, Taiwan)	
<b>Can We Re-Medicalise the Psychedelic Experience?</b>	18:00 - 19:00
<i>Speaker:</i> Guy Goodwin (Oxford, United Kingdom)	
 <i>Networking</i> 18:30 - 20:00	SR
<b>OPEN: Exhibition &amp; CINP Members' Lounge</b>	
 <i>Networking</i> 19:00 - 20:00	SR
<b>Welcome Reception</b>	

**Monday, 16. June 2025**

*Plenary*

09:10 - 10:10

PL

**Plenary 2: Keynote Lecture Sarah Medland**

*Chair:* Lucie Bartova (Vienna, Austria)

*Chair:* Miho Terunuma (Japan)

**Plenary Lecture 2: What have we learned from 15 years of collaborative neuroimaging research in the ENIGMA consortium**

09:10 - 10:10

*Speaker:* Sarah Medland (Brisbane, Australia)

*Networking*

09:30 - 17:00

SR

**OPEN: Exhibition & CINP Members' Lounge**

*Break*

10:10 - 10:50

SR

**Morning Coffee Break**

*Posters*

10:15 - 10:45

EXH

**Poster Session 1: Schizophrenia**

*Chair:* Noboru Hiroi (San Antonio, United States)

**Therapeutic potential of brain-penetrating nanoparticles containing a selective VIP receptor 2 (VIPR2) antagonist peptide for schizophrenia**

10:15 - 10:15

*Speaker:* Yukio Ago (Hiroshima, Japan)

**Maternal immune activation leads to schizophrenia-related behavioural and neurophysiological deficits in mothers and juvenile offspring**

10:15 - 10:15

*Speaker:* Francis Bambico (St. John's, Canada)

**Effects of prenatal cannabinoids exposure: assessing the role of the endocannabinoid system in a neurodevelopmental animal model of psychopathology**

10:15 - 10:15

*Speaker:* Vincenzo Micalè (Catania, Italy)

**Effect of GAD67 deletion in the thalamic reticular nucleus on sensory gating and sleep spindle activity**

10:15 - 10:15

*Speaker:* Hideki Miwa (Tokyo, Japan)

**Effect of developmental deficits in ventral hippocampal excitatory and inhibitory neurons in schizophrenia-relevant phenotypes in mice**

10:15 - 10:15

*Speaker:* Lalit K. Srivastava (Montreal, Canada)

**In vivo effects and molecular mechanism of a nanozyme-based artificial peroxisome on alleviating schizophrenia**

10:15 - 10:15

*Speaker:* Bo Pan (Yangzhou, China)

**Effects of antipsychotics and prenatal Poly I:C exposure on GSK3 $\beta$ -mediated signaling and NMDA/GABA receptors in the dorsal raphe nucleus of rats**

10:15 - 10:15

*Speaker:* Shiyang Chen (Fuzhou, China)

**Comparison of Brain age deviations among patients with schizophrenia, bipolar disorder, and major depressive disorder**

10:15 - 10:15

*Speaker:* Ya Mei Bai (Taipei, Taiwan)

<p><b>Neuromelanin Accumulation and Treatment Responsiveness in Patients with Schizophrenia: A Cross-Sectional Study with Neuromelanin-Sensitive MRI</b></p> <p><i>Speaker:</i> Fumihiko Ueno (Toronto, Canada)</p>	<p>10:15 - 10:15</p>
<p><b>Genetic evidence for the association between schizophrenia and obesity</b></p> <p><i>Speaker:</i> Shi-Heng Wang (Zhunan, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Validity of a smartphone application for self-monitoring psychiatric symptoms in patients with schizophrenia</b></p> <p><i>Speaker:</i> Cheol Park (Gwang-Ju, Korea, Republic of)</p>	<p>10:15 - 10:15</p>
<p><b>Temporal Dynamics of Gut Fungi in Drug-Naïve First-Episode Schizophrenia Patients During Antipsychotics Treatment</b></p> <p><i>Speaker:</i> Xue Zhao (Shanghai, China)</p>	<p>10:15 - 10:15</p>
<p><b>Using minor physical anomalies to predict treatment resistance in schizophrenia patients through machine learning</b></p> <p><i>Speaker:</i> Chih-Wei Lin (Tainan, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Distinct and Common Subcortical Functional Connectivity Revealed Across Three Major Psychiatric Disorders</b></p> <p><i>Speaker:</i> Duan-Pei Hung (Taipei, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Incidence of psychosis and its risk factors and mortality in North Korean Defectors compared to South Korean controls</b></p> <p><i>Speaker:</i> Thi-Hung Le (Jeonju, Korea, Republic of)</p>	<p>10:15 - 10:15</p>
<p><b>Screening of schizophrenia biomarkers based on proteomics and their application in early diagnosis</b></p> <p><i>Speaker:</i> Fang Dong (Beijing, China)</p>	<p>10:15 - 10:15</p>
<p><b>Impairment of the enhancement effect of perceived spatial separation on prepulse inhibition of Startle in first-episode Schizophrenia and clinical high risk for psychosis</b></p> <p><i>Speaker:</i> Yue Sun (Beijing, China)</p>	<p>10:15 - 10:15</p>
<p><b>Altered auditory network functional connectivity in psychotic disorder not other specified</b></p> <p><i>Speaker:</i> Woo-Sung Kim (Jeon-ju, Korea, Republic of)</p>	<p>10:15 - 10:15</p>
<p><b>Antipsychotic Medications and Risk Profiles Associated with Pneumonia in Patients with Schizophrenia Receiving Home-Care Case Management Intervention in Taiwan</b></p> <p><i>Speaker:</i> Chian-Jue Kuo (Taipei, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Saliva versus Plasma Therapeutic Drug Monitoring of Clozapine and Norclozapine</b></p> <p><i>Speaker:</i> Jimmy Lee (Singapore, Singapore)</p>	<p>10:15 - 10:15</p>
<p><b>Associations of polygenic risk scores differentiating attention-deficit hyperactivity disorder from autism spectrum disorder with cognitive and cortical alterations in schizophrenia patients</b></p> <p><i>Speaker:</i> Ayumi Kuramitsu (Gifu, Japan)</p>	<p>10:15 - 10:15</p>
<p><b>Structural brain differences in individuals at clinical high risk for psychosis</b></p> <p><i>Speaker:</i> Yimeng Wang (Beijing, China)</p>	<p>10:15 - 10:15</p>
<p><b>Leveraging white matter microstructural features to construct a high-performance diagnostic classifier for clinical high-risk for psychosis</b></p> <p><i>Speaker:</i> Zhenzhu Chen (Beijing, China)</p>	<p>10:15 - 10:15</p>
<p><b>Differences in the effects of antipsychotic drug-induced</b></p>	<p>10:15 - 10:15</p>

	<b>hyperprolactinemia in adolescent and adult schizophrenia patients: a retrospective pilot study</b>	
<i>Speaker:</i> Lei Zhang (Shanghai, China)		
	<b>The effect of bright light therapy on symptoms and cognitive function in patients with schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Ran Wang (Shijiazhuang, China)		
	<b>Problematic gambling and psychotic-like experiences: Findings from Japan</b>	10:15 - 10:15
	<b>Medicinal cannabis an mental health hospitalisation: an observational study</b>	10:15 - 10:15
<i>Speaker:</i> Fehim Puris (Brisbane, Australia)		
	<b>Relationship between clozapine:norclozapine ratio and cognitive function and employment status in treatment resistant schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Jiaqian Sun (Singapore, Singapore)		
	<b>The effect of sodium benzoate treatment for treatment resistant schizophrenia and its association with glutamate concentration: a pilot study with proton magnetic resonance spectroscopy</b>	10:15 - 10:15
<i>Speaker:</i> Yen Kuang Yang (Tainan, Taiwan)		
	<b>The association between cognitive inflexibility and decline deviation from fNIRS-measured brain function in schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Han-Yu Chuang (Taichung, Taiwan)		
	<b>Distinct signatures of OSSOs compared to SSDs and HC using graph theory analysis</b>	10:15 - 10:15
<i>Speaker:</i> Soyolsaikhan Odkhuu (Jeonju, Korea, Republic of)		
	<b>Effectiveness of long-acting injectable paliperidone palmitate on relapse prevention of schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Yung-Chieh Yen (Kaohsiung, Taiwan)		
	<b>Retrospective study for correlation with reducing antiparkinsonian anticholinergic drugs and adverse effects</b>	10:15 - 10:15
<i>Speaker:</i> Hiroataka Sekiguchi (Toyoake, Japan)		
	<b>In vivo assessments of tau pathologies in patients with late-onset psychosis: a PET study</b>	10:15 - 10:15
<i>Speaker:</i> Manabu Kubota (Chiba, Japan)		
	<b>Obesity associated with symptomatic remission in clozapine-treated individuals with treatment resistant schizophrenia</b>	10:15 - 10:15
<i>Speaker:</i> Daniel Chang (Singapore, Singapore)		
	<b>A case of cryptococcal meningitis &amp; Anti-NMDAR encephalitis in a patient with myelofibrosis in rural Victoria</b>	10:15 - 10:15
<i>Speaker:</i> Benjamin Neale (Traralgon, Australia)		
 <i>Symposium</i>		
10:50 - 12:05		PL
<b>Symposium 1: 5HT7 and 5HT4 Receptor Systems as Therapeutic Targets in Mood Disorders: What is New?</b>		
<i>Chair:</i> Lakshmi Yatham (Vancouver, Canada)		
	<b>Evaluating the Promise of the 5HT7 Receptor as a Therapeutic Target in Mood Disorders: A Review and New Neuroimaging Data</b>	10:50 - 11:15
<i>Speaker:</i> Paul Stokes (London, United Kingdom)		
	<b>A randomized double blind placebo controlled trial of lurasidone in improving cognitive impairment in euthymic patients with bipolar</b>	11:15 - 11:40

**disorder**

Speaker: Lakshmi N. Yatham (Vancouver, Canada)

**Effect of Antidepressant Treatment on 5-HT<sub>4</sub> Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive Disorder** 11:40 - 12:05

Speaker: Vibe Frokjae (Copenhagen, Denmark)

*Symposium*

10:50 - 12:05

S1

**Symposium 2: Moving Backward: From Treatment to Prevention in PTSD, Harnessing Neuroscience, Psychology, and Digital Tools**

Chair: Joseph Zohar (Ramat Gan, Israel)

**Scaling Digital Therapeutics for Post-Disaster Scenarios Using Generative Artificial Intelligence** 10:50 - 11:15

Speaker: Rahul Khanna (Melbourne, Australia)

**Enhancing resilience in leveraging digital therapeutics, AI, as Golden hour opportunities for personalized interventions in prevention and treatment of PTSD** 11:15 - 11:40

Speaker: Eric Vermetten (Leiden, Netherlands)

**A randomised controlled trial of a smartphone application as an early intervention to reduce symptoms of depression, anxiety and posttraumatic stress in first responders** 11:40 - 12:05

Speaker: Meaghan O'Donnell (Melbourne, Australia)

*Symposium*

10:50 - 12:05

S2

**Symposium 3: Update on the Clinical Utility of PsychoPharmacogenetics**

Chair: Allan Young (London, United Kingdom)

**Pharmacogenetic-supported prescribing for kids with mental health conditions** 10:50 - 11:15

Speaker: Chad Bousman (Calgary, Canada)

**A large RCT on a combinatorial pharmacokinetic pathway PGx** 11:15 - 11:40

Speaker: Malcolm Hopwood (Melbourne, Australia)

**An overview of the project exploring gene-drug pairs in dose guidance of antidepressants and antipsychotics** 11:40 - 12:05

Speaker: Roos van Westrhenen (Amsterdam, Netherlands)

*Session*

10:50 - 12:05

S3

**AsCNP Award Lecture**

Chair: Suresh Sundram (Clayton, Australia)

Chair: Shih-Ku Lin (Taipei, Taiwan)

**Exploring Asian Neuropsychopharmacological Research: Polypharmacy, Microglia, and Hikikomori Beyond Western Perspectives** 10:50 - 11:25

Speaker: Takahiro A. Kato (Hokkaido, Japan)

**Decoding Neuroimmune Mechanisms in Stress-Related Neuropsychiatric Disorders** 11:25 - 12:00

Speaker: Tomoyuki Furuyashiki (Kobe, Japan)

**Q&A, Discussion** 12:00 - 12:05

<i>Data Blitz Session</i>		
10:50 - 12:05		M1
<b>Data Blitz 1: Addiction related</b>		
<i>Chair:</i> Pin-Yen Lu (Kaohsiung, Taiwan)		
<b>Targeting opioid neurotransmission in borderline personality disorder with self-harming behavior: Preliminary findings of a [<sup>11</sup>C]NOP-1A positron emission tomography study</b>	10:50 - 10:56	
<i>Speaker:</i> Nathan Kolla (Saskatoon, Canada)		
<b>An electroencephalography connectome predictive model of craving for methamphetamine</b>	10:56 - 11:02	
<i>Speaker:</i> Di Zhao (Shanghai, China)		
<b>Repetitive Transcranial Magnetic Stimulation (rTMS) in the management of alcohol dependence and other substance abuse disorders - emerging data and clinical relevance</b>	11:02 - 11:08	
<i>Speaker:</i> Venu Gopal Jhanwar (Varanasi, India)		
<b>Adolescent THC Exposure Enhances Impulsivity in Adulthood: Insights from a WIN 55,212-2 Self-Administration Mouse Model</b>	11:08 - 11:14	
<i>Speaker:</i> Elena Martín García (Barcelona, Spain)		
<b>Disruption of kinematic phenotypes induced by cannabinoid agonist and harmaline in marker-based 3D motion capture of freely moving mice</b>	11:14 - 11:20	
<i>Speaker:</i> Bogna Ignatowska-Jankowska (Onna, Japan)		
<b>Medication-seeking behaviors and correlated characteristics of Zolpidem users in Taiwan - a shared patient network analysis</b>	11:20 - 11:26	
<i>Speaker:</i> Wei-Chen Lee (New Taipei City, Taiwan)		
<b>Symptom based pharmacotherapy of borderline personality disorder</b>	11:26 - 11:32	
<i>Speaker:</i> Rajesh Nagpal (New Delhi, India)		
<b>Discussion, Q&amp;A</b>	11:32 - 12:05	
<i>Meet the Experts / Campfire Session</i>		
10:50 - 11:50		M2
<b>Campfire Session:</b>		
<b>The Good, the Bad, and the Rejected: Tales from Editors (LIMITED SEATS)</b>		
<i>Chair:</i> Gregers Wegener (Aarhus, Denmark)		
<b>The Good, the Bad, and the Rejected: Tales from Editors</b>	10:50 - 11:50	
<i>Speaker:</i> Gregers Wegener (Aarhus, Denmark)		
<i>Speaker:</i> Anthony Grace (Pittsburgh, United States)		
<i>Spotlight Session</i>		
12:15 - 13:15		PL
<b>Spotlight Session 1: Neuropsychopharmacology of Seizure and Psychotic Disorders</b>		
<i>Chair:</i> Johnny Lokin (Philippines)		
<b>Overlapping Pathophysiology of Seizures and Psychosis</b>	12:15 - 12:35	
<i>Speaker:</i> Marc Fernandez (Philippines)		
<b>The Role of Neuroinflammation in the Intersection of Epilepsy and Psychosis</b>	12:35 - 12:55	
<i>Speaker:</i> Gerardo Salazar (Philippines)		
<b>Novel Therapeutic Targets in Epilepsy-Psychosis Spectrum Disorders</b>	12:55 - 13:15	
<i>Speaker:</i> Alejandro Baroque II (Philippines)		

Data Blitz Session  
12:15 - 13:15 S1

**Data Blitz 2: Depression characterization**

Chair: Diego A. Pizzagalli (Belmont, United States)

**Risk factors and psychotropic medication influence in the progression from major depression to bipolar disorder: findings from a 16-year study** 12:15 - 12:21

Speaker: Ying-Ting Chao (Taipei, Taiwan)

**Plasma Neurofilament Light and Glial Fibrillary Acidic Protein are Elevated in Bipolar Disorder: Evidence for Neuroprogression and Astrogliosis** 12:21 - 12:27

Speaker: Matthew Kang (Melbourne, Australia)

**The neuroanatomy of postpartum depression: Insights from a cross-sectional structural MRI study** 12:27 - 12:33

Speaker: Sofia Attolini (Berlin, Germany)

**Correlation of Mood Symptoms and the Seasonal Variation of Vitamin D Levels in Taiwanese Mood Disorder Patients and Healthy Individuals: A Comparative Cohort Study** 12:33 - 12:39

Speaker: Chun-I Liu (Taipei, Taiwan)

**Integration analysis of gut microbiome and serum proteome in patients with unipolar and bipolar depressive episodes** 12:39 - 12:45

Speaker: Cuixia An (Shijiazhuang, China)

**Fibroblast growth factor 2 modulates central monoaminergic neurons *in vivo*** 12:45 - 12:51

Speaker: Ruslan Paliokha (Bratislava, Slovakia)

**Small molecule-driven Arginase-1<sup>+</sup> microglial phenotype suppresses chronic stress-induced microglial engulfment and neuroinflammation via a PPAR $\gamma$ -dependent mechanism** 12:51 - 12:57

Speaker: Najun Yuan (Guangzhou, China)

**Assessment of resting state functional Magnetic Resonance Imaging (fMRI) connectivity among patients with major depressive disorder** 12:57 - 13:03

Speaker: Paramdeep Singh (Bathinda, India)

**Evaluating apelin as a potential biomarker in major depressive disorder: correlation with clinical symptomatology** 13:03 - 13:09

Speaker: Enkhmurun Chibaatar (Kitakyushu, Japan)

**Progress of transcriptomic and epigenomes study in the depression and suicide study** 13:09 - 13:15

Speaker: Qingzhong Wang (Birmingham, United States)

Data Blitz Session  
12:15 - 13:15 S2

**Data Blitz 3: Mood, clinical-related**

Chair: Ya Mei Bai (Taipei, Taiwan)

**The effects of ebselen addition on Glx and glutamate levels in the anterior cingulate cortex in clinically depressed patients taking antidepressant medication** 12:15 - 12:21

Speaker: Fitri Fareez Ramli (Oxford, United Kingdom)

**Adherence and engagement metrics with the novel prescription digital therapeutic, CT-152** 12:21 - 12:27

Speaker: Tarolyn Carlton (Princeton, United States)

**Comparative analysis of gut microbiota and functional pathways in** 12:27 - 12:33

	<b>antidepressant-treated vs. antidepressant-naïve depression patients and healthy controls</b>	
<i>Speaker:</i> Shih Kai Lin (Taipei, Taiwan)		
	<b>Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: results of a systematic review and meta-analysis</b>	12:33 - 12:39
<i>Speaker:</i> Jessica Green (Geelong, Australia)		
	<b>Targeting Ruminative Thinking Through Brain Training</b>	12:39 - 12:45
<i>Speaker:</i> Katie Douglas (Christchurch, New Zealand)		
	<b>Emotional faces memory task performance and clinical outcomes for the novel prescription digital therapeutic, CT-152</b>	12:45 - 12:51
<i>Speaker:</i> Jeffrey Cochran (Princeton, United States)		
	<b>Assessing and managing cigarette smoking among psychiatric inpatients: clinical and sociodemographic implications</b>	12:51 - 12:57
<i>Speaker:</i> Maurizio Pompili (Rome, Italy)		
	<b>The adverse experiences, social support, and neurochemical alterations in bipolar disorder: a focus on history of psychotic features</b>	12:57 - 13:03
<i>Speaker:</i> Sriyani Padmalatha Konara Mudiyansele (Tainan, Taiwan)		
	<b>Investigating the hemodynamic response to iTBS of the left DLPFC: a concurrent iTBS/fNIRS study</b>	13:03 - 13:09
<i>Speaker:</i> Weili Xia (Hong Kong, China)		
	<b>Mitochondrial DNA copy number as a mediator of the relationship between insulin resistance and cognitive function in patients with euthymic bipolar disorder</b>	13:09 - 13:15
<i>Speaker:</i> Tsung-Han Tsai (Tainan, Taiwan)		
 <i>Featured Communication</i>		
12:15 - 13:15		S3
<b>Featured Communication 1: Depression clinical</b>		
<i>Chair:</i> Yen Kuang Yang (Tainan, Taiwan)		
	<b>Efficacy of Silexan in Patients with a Major Depressive Episode - Results from a Multi-centre, Double-blind, Randomised, Placebo- and Reference-controlled Phase III Trial</b>	12:15 - 12:30
<i>Speaker:</i> Siegfried Kasper (Vienna, Austria)		
	<b>Changes in Quality of Life and Productivity Gain among Esketamine Responders in a Real-world Study in Australia and New Zealand</b>	12:30 - 12:45
<i>Speaker:</i> Malcolm Hopwood (Melbourne, Australia)		
	<b>Polygenic risk analyses of venlafaxine-related side effects in older adults with depression</b>	12:45 - 13:00
<i>Speaker:</i> Daniel Mueller (Toronto, Canada)		
	<b>Discussion, Q&amp;A</b>	13:00 - 13:15
 <i>Selected Colloquium</i>		
12:15 - 13:15		M1
<b>Selected Colloquium 6: Precision Psychiatry CINP GNC symposium: From biomarker discovery to therapeutic innovation toward personalized mental health care</b>		
<i>Chair:</i> Bernhard Baune (Münster, Germany)		
	<b>Precision psychiatry: contributions from brain imaging, genetics, IPSC</b>	12:15 - 12:35
<i>Speaker:</i> Dan Rujescu (Wien, Austria)		
	<b>Decoding the biomolecular landscape of psychiatric disorders for</b>	12:35 - 12:55

<b>improving patient stratification</b>		
<i>Speaker:</i> Stefano Comai (Padova, Italy)		
<b>Translational implications of ongoing protocols in Precision Psychiatry</b>	12:55 - 13:15	
<i>Speaker:</i> Bernhard Baune (Münster, Germany)		
 <i>Meet the Experts / Campfire Session</i>		
12:15 - 13:15		M2
<b>Meet the Expert 1: OCD (LIMITED SEATS)</b>		
<i>Chair:</i> Joseph Zohar (Ramat Gan, Israel)		
<b>OCD: Case Discussions</b>	12:15 - 13:15	
<i>Speaker:</i> Joseph Zohar (Ramat Gan, Israel)		
<i>Speaker:</i> Zhen Wang (China)		
<i>Speaker:</i> Vlasios Brakoulias (Australia)		
 <i>Break</i>		
13:15 - 14:40		SR
<b>Lunch Break</b>		
 <i>Sponsored Symposium</i>		
13:25 - 14:25		S2
<b>Sponsored Lunch Symposium</b>		
 <i>Sponsored Symposium</i>		
13:25 - 14:25		S3
<b>Sponsored Lunch Symposium</b>		
 <i>Symposium</i>		
14:40 - 15:55		PL
<b>Symposium 4: Psychedelics: From Bench to Clinic</b>		
<i>Chair:</i> Bernard Lerer (Jerusalem, Israel)		
<b>Distinct Behavioral and Pharmacological Effects of Psilocybin and Lisuride</b>	14:40 - 15:05	
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)		
<b>Psychedelics and OCD: translational approaches</b>	15:05 - 15:30	
<i>Speaker:</i> Bernard Lerer (Jerusalem, Israel)		
<b>Clinical evidence and applications of psychedelics for mental illnesses</b>	15:30 - 15:55	
<i>Speaker:</i> Hideaki Tani (Tokyo, Japan)		
 <i>Symposium</i>		
14:40 - 15:55		S1
<b>Symposium 5: New roles for neuromodulation in cognitive function and related disorders</b>		
<i>Chair:</i> Satoshi Kida (Tokyo, Japan)		
<b>Memory modulation by dopamine-cAMP signal transduction pathways</b>	14:40 - 15:05	
<i>Speaker:</i> Satoshi Kida (Tokyo, Japan)		
<b>A modulatory brain circuit involved in the cognitive control of choice and decision-making and its disorders</b>	15:05 - 15:30	
<i>Speaker:</i> Bernard Balleine (Sydney, Australia)		
<b>Neuromodulation of amygdala-mediated affective learning</b>	15:30 - 15:55	

Speaker: Andrew Holmes (Bethesda, United States)

Symposium

14:40 - 15:55

S2

**Symposium 6: Pre- and postnatal maternal health and child outcomes**

Chair: Cristiana Cruceanu (Stockholm, Sweden)

**The long-term effects of reproductive experience on anxiety and its pharmacological treatment: a cross-species approach in rats and humans**

14:40 - 15:05

Speaker: Jodie Pestana (Sydney, Australia)

**Prenatal stress exposure shapes corticogenesis through cell fate and gene regulatory networks with implications for neurodevelopmental disorders**

15:05 - 15:30

Speaker: Cristiana Cruceanu (Stockholm, Sweden)

**Delineating the impact of early life adversity on the cellular and molecular architecture of the human brain.**

15:30 - 15:55

Speaker: Natalie Matosin (Sydney, Australia)

Spotlight Session

14:40 - 15:40

S3

**Spotlight Session 2: NextGen Taiwan Researchers Forum**

Chair: Po-See Chen (Taiwan)

**The effect of combined theta burst stimulation on functional connectivity of the thalamus and putamen in patients with gambling disorder**

14:40 - 14:46

Speaker: Shu-Wei Liu (Taipei, Taiwan)

**Distinct and Common Subcortical Functional Connectivity Revealed Across Three Major Psychiatric Disorders**

14:46 - 14:52

Speaker: Duan-Pei Hung (Taipei, Taiwan)

**Distinctive association patterns between topological properties of brain structural networks and social cognition in euthymic bipolar disorder**

14:52 - 14:58

Speaker: Tsai Chung Hahn (Tainan, Taiwan)

**Predicting rTMS treatment response in depression: use of machine learning models to identify the roles of metabolic and clinical factors**

14:58 - 15:04

Speaker: I Chun Liu (Tainan City, Taiwan)

**Using Classification and Regression Tree Modelling to Investigate Low-Dose Ketamine's Effect on Remission of Suicidal Symptoms Among Patients with Treatment-Resistant Depression and Strong Suicidal Thought**

15:04 - 15:10

Speaker: Ping Chung Wu (Taipei, Taiwan)

**Mitochondrial DNA copy number as a mediator of the relationship between insulin resistance and cognitive function in patients with euthymic bipolar disorder**

15:10 - 15:16

Speaker: Tsung-Han Tsai (Tainan, Taiwan)

**Abnormalities of Subcortical Brain Volume throughout the Psychosis Course**

15:16 - 15:22

Speaker: Yi-An Liao (Taipei, Taiwan)

**Age-specific variations in antidepressant efficacy of transcranial magnetic stimulation for treatment-resistant depression: a real-world retrospective study**

15:22 - 15:28

Speaker: Jia Shyun Jeng (Taipei, Taiwan)

<p><b>OPRM1 A118G Polymorphisms and Naltrexone Treatment Response among Taiwanese Patients with Alcohol Use Disorder</b></p> <p><i>Speaker:</i> Yan-Jiun Hung (Taipei, Taiwan)</p>	<p>15:28 - 15:34</p>
<p><b>Cannabidiol mitigates cognitive deficits in a mouse model of Alzheimer's disease</b></p> <p><i>Speaker:</i> Yi-Chia Chen (Tainan, Taiwan)</p>	<p>15:34 - 15:40</p>
<p><i>Featured Communication</i> 14:40 - 15:55</p>	
<p>M1</p>	
<p><b>Featured Communication 2: Different clinical disorders</b></p> <p><i>Chair:</i> Christopher Davey (Melbourne, Australia)</p>	
<p><b>The efficacy of deep brain stimulation of combined anterior limb of internal capsule and nucleus accumbens for treatment-refractory obsessive-compulsive disorder: a randomised, double-blinded, and sham-controlled study</b></p> <p><i>Speaker:</i> Jiayue Cheng (Shanghai, China)</p>	<p>14:40 - 14:55</p>
<p><b>Comprehensive gene expression analysis of GABAergic neurons-derived from iPS cells of patients with fibromyalgia accompanied by psychiatric symptoms</b></p> <p><i>Speaker:</i> Naoko Kuzumaki (Tokyo, Japan)</p>	<p>14:55 - 15:10</p>
<p><b>Moderated Discussion, Q&amp;A</b></p>	
<p>15:10 - 15:40</p>	
<p><i>Meet the Experts / Campfire Session</i> 14:40 - 15:40</p>	
<p>M2</p>	
<p><b>Meet the Expert 2: PTSD (LIMITED SEATS)</b></p> <p><i>Chair:</i> Eric Vermetten (Leiden, Netherlands)</p>	
<p><b>PTSD: Case Discussions</b></p>	
<p><i>Speaker:</i> Eric Vermetten (Leiden, Netherlands)</p>	<p>14:40 - 15:40</p>
<p><i>Speaker:</i> Meaghan O'Donnel (Melbourne, Australia)</p> <p><i>Speaker:</i> Rahul Khanna (Melbourne, Australia)</p>	
<p><i>Posters</i> 15:55 - 16:35</p>	
<p>EXH</p>	
<p><b>Poster Session 2: Addiction Disorders, Sleep Disorders, Variable</b></p> <p><i>Chair:</i> Zhen Wang (China)</p>	
<p><b>Sex-Specific Effects of Repeated Ketamine Exposure on Locomotor Activity in Mice: Influence of Social and Isolated Housing Conditions</b></p> <p><i>Speaker:</i> Yuki Moriya (Tokyo, Japan)</p>	<p>15:55 - 15:55</p>
<p><b>Dynamic rewiring of neural circuits in the prelimbic cortex in meth abstinence</b></p> <p><i>Speaker:</i> Sai Shi (Shanghai, China)</p>	<p>15:55 - 15:55</p>
<p><b>Oxytocinergic input from the paraventricular nucleus to the nucleus accumbens core modulates methamphetamine-conditioned place preference</b></p> <p><i>Speaker:</i> Manqing Wu (Shanghai, China)</p>	<p>15:55 - 15:55</p>
<p><b>Psilocybin does not induce conditioned place preference, but modifies behavioral patterns in Sprague-Dawley rats</b></p> <p><i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)</p>	<p>15:55 - 15:55</p>
<p><b>The Bidirectional Claustrum-Anterior Cingulate Cortex Circuit Differentially Regulates Methamphetamine Taking and Seeking in a Rodent Self-Administration Model</b></p> <p><i>Speaker:</i> Manqing Wu (Shanghai, China)</p>	<p>15:55 - 15:55</p>

<b>N-Acetylcysteine Mitigates Reinstatement of Ketamine Seeking in Rats</b>	15:55 - 15:55
<b>Salience network alterations related to personality traits in adolescents with excessive smartphone use</b>	15:55 - 15:55
<i>Speaker:</i> Min Kyung Hu (Seoul, Korea, Republic of)	
<b>Shared genetic architectures between methamphetamine use and other psychiatric disorders</b>	15:55 - 15:55
<i>Speaker:</i> Yen-Feng Lin (Zhunan Town, Miaoli County, Taiwan)	
<b>OPRM1 A118G Polymorphisms and Naltrexone Treatment Response among Taiwanese Patients with Alcohol Use Disorder</b>	15:55 - 15:55
<i>Speaker:</i> Yan-Jiun Hung (Taipei, Taiwan)	
<b>The effect of combined theta burst stimulation on functional connectivity of the thalamus and putamen in patients with gambling disorder</b>	15:55 - 15:55
<i>Speaker:</i> Shu-Wei Liu (Taipei, Taiwan)	
<b>Comparison of features of relapse risk between alcohol-dependent individuals in Japan and Australia through use of validated self-rating scale: the Alcohol Relapse Risk Scale</b>	15:55 - 15:55
<i>Speaker:</i> Shijia Winson Lu (Sydney, Australia)	
<b>Association between venlafaxine use and the risk of substance withdrawal in patients with nonopioid substance use</b>	15:55 - 15:55
<i>Speaker:</i> Shyh-Yuh Wei (Tainan, Taiwan)	
<b>The effects of yoga therapy on stigma in patients with alcohol use disorders: A single-blind randomized controlled study (Preliminary report)</b>	15:55 - 15:55
<i>Speaker:</i> Saeko Ikai-Tani (Tokyo, Japan)	
<b>HTR2A expression levels are correlated with the release of neurofilament light chain</b>	15:55 - 15:55
<i>Speaker:</i> Hsiang-Wei Kuo (Miaoli County, Taiwan)	
<b>Clinical value of predicting relapse within 3 months in patients with alcohol dependence based on functional near-infrared spectroscopy during a verbal fluency task</b>	15:55 - 15:55
<i>Speaker:</i> Lan Wang (Shijiazhuang, China)	
<b>Game motivation affects whether players benefit or suffer from games</b>	15:55 - 15:55
<i>Speaker:</i> Yuchen Huang (Beijing, China)	
<b>Is immunological gluten sensitivity a risk factor of development of eating disorder with low body weight?</b>	15:55 - 15:55
<i>Speaker:</i> Hisashi Yamada (Nishinomiya, Japan)	
<b>The relationship between sleep quality and neurocognitive function in the geriatric depression: a case-control study</b>	15:55 - 15:55
<i>Speaker:</i> Yu-Shu Huang (Taoyuan, Taiwan)	
<b>Ramelteon reduced anxiety/depression and sleep problems among shift workers</b>	15:55 - 15:55
<i>Speaker:</i> Chin-Bin Yeh (Taipei, Taiwan)	
<b>The population based risk of obstructive sleep apnea and psychiatric disorder</b>	15:55 - 15:55
<i>Speaker:</i> Chuan-Yi Kao (Taichung, Taiwan)	
<b>Sex differences in the amygdala and bed nucleus of the stria terminalis circuit involving in memory retrieval of vicarious fear conditioning</b>	15:55 - 15:55

Speaker: Yi-Han Liao (Chiayi City, Taiwan)

**Nucleoporin POM121 confer passive nuclear translocation and envelop integrity via Sigma-1 receptor in poly-PR-induced C9orf72 ALS** 15:55 - 15:55

Speaker: Hsiang-En Wu (Baltimore, United States)

**Distinct effects of synthetic GPR17 antagonists on cellular signaling in recombinant HEK293 cells and native oligodendroglial cell backgrounds** 15:55 - 15:55

Speaker: Jack McDonald (Melbourne, Australia)

**Stress and Airborne Oxytocin Effects on Male Mice' Sex Motives** 15:55 - 15:55

Speaker: Li-Han Sun (Tainan, Taiwan)

**Dietary cuprizone and gestational THC exposure both induce localized depletion of brain copper** 15:55 - 15:55

Speaker: Brittney Lins (Bentley, Australia)

**A multiverse meta-analysis of oxytocin administration studies** 15:55 - 15:55

Speaker: Heemin Kang (Oslo, Norway)

**Chronic exposure to air pollutants leads to cognitive decline mediated by gut-derived metabolite TMAO in adult mice** 15:55 - 15:55

Speaker: Akhlaq Hussain (Kowloon, Hong Kong)

**Psychiatric risks of corticosteroids: findings from a systematic review and meta-analysis** 15:55 - 15:55

Speaker: Keisuke Kusudo (Tokyo, Japan)

**Barriers to international research in neuropsychopharmacology for early career researchers - preliminary data from the 1st CINP fellowship program survey** 15:55 - 15:55

Speaker: Gina M. Kemp (Montreal, Canada)

**Clinical Case Report of a Patient Admitted to a Psychiatric Emergency Unit in a Referral Hospital in a Southern State of Brazil, with First-Episode Psychosis** 15:55 - 15:55

**Sensitivity and specificity of anti-gliadin IgG antibodies for patients with gluten intolerance, and their psychiatric/physical symptoms** 15:55 - 15:55

Speaker: Mikuni Motoyama (Nishinomiya, Japan)

**Chronic morphine exposure alters the molecular cargo of brain-derived extracellular vesicles: upregulation of ARC and neuroplasticity-related proteins** 15:55 - 15:55

Speaker: Pedro Gobira (Aarhus, Denmark)

**Early assertive pharmacotherapy intervention study for stimulant associated psychosis—a 24-month prospective randomized controlled trial** 15:55 - 15:55

Speaker: Albert Kar Kin Chung (Hong Kong, Hong Kong)

**Secondary effects of psychopharmacological drugs as primary effects in forensic psychiatry. Based on the swiss model** 15:55 - 15:55

Speaker: Manola Schlemper (Windisch, Switzerland)

**Combined traditional Chinese and Western medicine reduces dementia risk in insomnia patients: a real-world cohort study** 15:55 - 15:55

Speaker: Yu-Ching Huang (Taipei, Taiwan)

**Large-scale profiling of coding and long noncoding transcriptomes in the hippocampus of mice acutely exposed to vaporized THC** 15:55 - 15:55

Speaker: Mi Ran Choi (Suwon, Korea, Republic of)

**The neurobiological foundation for physical exercise** 15:55 - 15:55

<b>recommendations in reducing symptoms of ADHD</b>		
<i>Speaker:</i> Anna Szczegieliak (Katowice, Poland)		
	<b>How testosterone administration affects learning to avoid harm in healthy men: a double-blind, placebo-controlled study</b>	15:55 - 15:55
<i>Speaker:</i> Yin Wu (Hong Kong, Hong Kong)		
	<b>Systematic review of the role of gut microbiota in the pathophysiology of ADHD and the potential of probiotic strains for the management of ADHD symptoms</b>	15:55 - 15:55
<i>Speaker:</i> Adicitra Auriel Bestari (Surabaya, Indonesia)		
 <i>Break</i>		
15:55 - 16:35		SR
<b>Afternoon Coffee Break</b>		
 <i>Plenary</i>		
16:35 - 17:35		PL
<b>Plenary 3: Keynote Lecture Paul Kenny</b>		
<i>Chair:</i> Atsumi Nitta (Japan)		
<i>Chair:</i> Lih-Chu Chiou (Taipei, Taiwan)		
	<b>Cellular mechanisms of nicotine craving</b>	16:35 - 17:35
<i>Speaker:</i> Paul Kenny (New York, United States)		
 <i>Session</i>		
17:40 - 18:40		PL
<b>AsCNP Symposium: The third survey of the Research in East Asia Psychotropic Prescription Patterns on Antidepressants</b>		
<i>Chair:</i> Shih-Ku Lin (Taipei, Taiwan)		
	<b>Polypharmacy and Prescription Patterns of Antidepressants in REAP AD3</b>	17:40 - 18:00
<i>Speaker:</i> Tian-Mei Si (Beijing, China)		
	<b>Diagnostic Distribution of Antidepressant Users: Findings from the REAP-AD3</b>	18:00 - 18:20
<i>Speaker:</i> Yueh-Pin Lin (Taipei, Taiwan)		
	<b>Current Trend of the Patterns of Antidepressants in Asian Countries: Evidence from REAP-AD3</b>	18:20 - 18:40
<i>Speaker:</i> Takahiro A. Kato (Hokkaido, Japan)		
 <i>Spotlight Session</i>		
17:40 - 18:40		S1
<b>Spotlight Session 3: Many Faces of Limbic Encephalitis</b>		
<i>Chair:</i> Anna Lizza Mañalac (Pampanga, Philippines)		
	<b>Autoimmune Mechanisms and Antibody Profiling in Limbic Encephalitis</b>	17:40 - 17:55
<i>Speaker:</i> Arnold Angelo Pineda (Philippines)		
	<b>Psychiatric Manifestations of Limbic Encephalitis: Neuropsychopharmacological Perspectives</b>	17:55 - 18:10
<i>Speaker:</i> Johnny Lokin (Philippines)		
	<b>Therapeutic Strategies: Immunomodulation and Beyond</b>	18:10 - 18:25
<i>Speaker:</i> Celeste Pena (Philippines)		
	<b>Cognitive and Behavioral Sequelae of Limbic Encephalitis</b>	18:25 - 18:40
<i>Speaker:</i> Roberto Bolivar Capistrano (Philippines)		

<i>Featured Communication</i>	
17:40 - 18:40	S2
<b>Featured Communication 3: Dopamine/Schizophrenia</b>	
<i>Chair:</i> Anthony Grace (Pittsburgh, United States)	
<b>Leveraging digital enablers to amplify the evidence for clinical practice in treatment-resistant schizophrenia</b>	17:40 - 17:55
<i>Speaker:</i> Kannan Subramaniam (Auckland, New Zealand)	
<b>Nitrous oxide exerts rewarding effect via regulating D1 receptor and BDNF pathway in ventral tegmental area-nucleus accumbens dopamine circuit</b>	17:55 - 18:10
<i>Speaker:</i> Zhang-Jin Zhang (Hong Kong, Hong Kong)	
<b>Raloxifene induces sex-specific changes in anxiety- and dopamine-related behaviours in adolescent offspring following prenatal immune activation</b>	18:10 - 18:25
<i>Speaker:</i> Tertia Purves-Tyson (Sydney, Australia)	
<b>Q&amp;A, Discussion</b>	18:25 - 18:40
 <i>Networking</i>	
17:40 - 19:40	S3
<b>Japan Networking Reception</b>	
 <i>Selected Colloquium</i>	
17:40 - 18:40	M1
<b>Selected Colloquium 2: Adverse events: a neglected area in pharmacotherapeutics</b>	
<i>Chair:</i> Siegfried Kasper (Vienna, Austria)	
<b>Adverse effects and the treatment of resistant depression</b>	17:40 - 18:00
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)	
<b>Are side effects necessary for antidepressive treatment: the Psilocybin experience</b>	18:00 - 18:20
<i>Speaker:</i> Siegfried Kasper (Vienna, Austria)	
<b>The WPA/CINP study on Tool development for Psychosis (WPA/CINP TOP study): rational and design</b>	18:20 - 18:40
<i>Speaker:</i> Konstantinos Fountoulakis (Thessaloniki, Greece)	
 <i>Meet the Experts / Campfire Session</i>	
17:40 - 18:40	M2
<b>Meet the Expert 3: Bipolar Disorder (LIMITED SEATS)</b>	
<i>Chair:</i> Philip Mitchell (Australia)	
<b>Bipolar Disorder: Case Discussions</b>	17:40 - 18:40
<i>Speaker:</i> Allan Young (London, United Kingdom)	
<i>Speaker:</i> Michael Berk (Geelong, Australia)	
<i>Speaker:</i> Philip Mitchell (Australia)	

**Tuesday, 17. June 2025**

*Sponsored Symposium*

08:00 - 09:00

S2

**Sponsored Breakfast Symposium**

*Plenary*

09:10 - 10:10

PL

**Plenary 4: Keynote Lecture Susan Shur-Fen Gau**

*Chair:* Andi Tanra (Makassar, Indonesia)

*Chair:* Lukoye Atwoli (Kenya)

**Plenary Lecture 4: Characterizing Attention-deficits Hyperactivity Disorder: Insights from Neurocognition, Imaging, Pharmacotherapy, and the Gut-Brain Axis**

09:10 - 10:10

*Speaker:* Susan Shur-Fen Gau (Taipei, Taiwan)

*Networking*

09:30 - 17:00

SR

**OPEN: Exhibition & CINP Members' Lounge**

*Break*

10:10 - 10:50

SR

**Morning Coffee Break**

*Posters*

10:15 - 10:45

EXH

**Poster Session 3: Bipolar Disorders, OCD, PTSD, Variable**

*Chair:* Shao-Han Chang (Taipei, Taiwan)

**Exacerbation of brain stress-related inflammation associated with disruption of inflammatory suppression mechanisms in hypothalamic microglia under conditions of cancer cachexia**

10:15 - 10:15

*Speaker:* Yukari Suda (Tokyo, Japan)

**Assessment of the impact of premorbid traits on allostatic load of caregivers**

10:15 - 10:15

*Speaker:* Carolina Remedi (Cordoba, Argentina)

**Discrimination Between Healthy Participants and People with Panic Disorder Based on Polygenic Scores for Psychiatric Disorders and for Intermediate Phenotypes using Machine Learning**

10:15 - 10:15

*Speaker:* Kazutaka Ohi (Gifu, Japan)

**A Single Yoga Session for Anxiety and Stress in Adults with or without Mental Illnesses: A Scoping Review**

10:15 - 10:15

*Speaker:* Saeko Ikai-Tani (Tokyo, Japan)

**Preliminary study on visuospatial impairment examined by eye tracking in patients with Obsessive-Compulsive Disorder**

10:15 - 10:15

*Speaker:* Yukihiko Hosoi (Hyogo, Japan)

**Comparison of the efficacy and tolerability between paroxetine and escitalopram in patients with Obsessive-Compulsive Disorder in real-world clinical settings in Japan**

10:15 - 10:15

*Speaker:* Keiichiro Mukai (Nishinomiya, Japan)

**A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: A case report and literature review**

10:15 - 10:15

*Speaker:* Pornjira Pariwatcharakul (Bangkok, Thailand)

<p><b>Exploring functional connectivity in anxiety: the role of the hippocampus, insula, and amygdala during a ketamine infusion</b></p> <p><i>Speaker:</i> Samantha Graf (Vienna, Austria)</p>	<p>10:15 - 10:15</p>
<p><b>Focus on orexin-A in obese diabetes rats: upregulation of orexin-A receptor in the diabetic brain</b></p>	<p>10:15 - 10:15</p>
<p><b>Using spatially resolved single-nucleus multi-omics approach to understand how adversity contributes to psychiatric disorders</b></p> <p><i>Speaker:</i> Tamim Ahsan (Wollongong, Australia)</p>	<p>10:15 - 10:15</p>
<p><b>Lipid core-encapsulated cannabidiol causes anxiolytic- and panicolytic-like effects on defensive behavior elicited in mice by <i>Bothrops jararaca</i> lancehead pit vipers</b></p> <p><i>Speaker:</i> Norberto Cysne Coimbra (Ribeirão Preto, Brazil)</p>	<p>10:15 - 10:15</p>
<p><b>Accelerated brain aging in young women with post-traumatic stress disorder</b></p> <p><i>Speaker:</i> Yoonji Joo (Seoul, Korea, Republic of)</p>	<p>10:15 - 10:15</p>
<p><b>Development of key components in a small, portable device for the therapeutic monitoring of lithium</b></p> <p><i>Speaker:</i> Seetal Dodd (Geelong, Australia)</p>	<p>10:15 - 10:15</p>
<p><b>C-reactive protein and response to add-on dextromethorphan treatment in bipolar disorders: Results from a placebo-controlled trial</b></p> <p><i>Speaker:</i> Chih-Chun Huang (Tainan, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Distinctive association patterns between topological properties of brain structural networks and social cognition in euthymic bipolar disorder</b></p> <p><i>Speaker:</i> Tsai Chung Hahn (Tainan, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Altered prefrontal cortex-based functional connectivity and trait impulsivity among patients with bipolar disorder and history of suicide attempts</b></p> <p><i>Speaker:</i> Mao-Hsuan Huang (Taipei, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Differentially expressed platelet oncoproteins and their association with plasma Programmed cell death ligand 1 in bipolar manic patients</b></p> <p><i>Speaker:</i> Li Jhang (Taipei City, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Dynamic Postural Control in remitted Bipolar I Disorder: A CDP study</b></p> <p><i>Speaker:</i> Abubacker Rahina (Bengaluru, India)</p>	<p>10:15 - 10:15</p>
<p><b>Effectiveness of long-acting injectable aripiprazole on relapse prevention of bipolar I disorder</b></p> <p><i>Speaker:</i> Chiao-Hsin Yen (Debrecen, Hungary)</p>	<p>10:15 - 10:15</p>
<p><b>Cognitive inflexibility associated with decline deviation from fNIRS-measured brain function in mood disorders</b></p> <p><i>Speaker:</i> Yun-Hsuan Chang (Tainan, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Delayed onset post-stroke mania, a case report and literature review</b></p> <p><i>Speaker:</i> Jason Hong-Yi Chang (Taipei, Taiwan)</p>	<p>10:15 - 10:15</p>
<p><b>Therapeutic drug monitoring for antipsychotic medication to estimate drug adherence in Japanese patients with psychiatric disorders</b></p> <p><i>Speaker:</i> Wataru Tanichi (Gifu, Japan)</p>	<p>10:15 - 10:15</p>
<p><b>Risk of agranulocytosis and neutropenia in patients with</b></p>	<p>10:15 - 10:15</p>

<b>Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis</b>	
<i>Speaker:</i> Nahathai Limveeraprajak (Bangkok, Thailand)	
<b>Psychotropics use and occurrence of falls in hospitalized patients: a matched case-control study</b>	10:15 - 10:15
<i>Speaker:</i> Chihiro Morishita (Tokyo, Japan)	
<b>Epigenetic Insights into Social Cognition: Sex-Specific Influences of BDNF and Oxytocin Receptor Gene Methylation</b>	10:15 - 10:15
<i>Speaker:</i> Hye Yoon Park (Yongin, Korea, Republic of)	
<b>The preliminary analysis of yoga therapy on burnout among medical staff: A single-arm pre-post intervention</b>	10:15 - 10:15
<i>Speaker:</i> Saeko Ikai-Tani (Tokyo, Japan)	
<b>Lorazepam and survival in patients with pancreatic cancer: a retrospective cohort study</b>	10:15 - 10:15
<i>Speaker:</i> Jin Woo Park (Seoul, Korea, Republic of)	
<b>Neuropsychologically-Based Clustering of Psychosomatic Patients</b>	10:15 - 10:15
<i>Speaker:</i> Tzu-Ting Chen (Douliu, Taiwan)	
<b>A randomised controlled trial of an AI-enabled mental health intervention for generalized anxiety disorder symptoms</b>	10:15 - 10:15
<i>Speaker:</i> Allan Young (London, United Kingdom)	
<b>Changes in peripheral immune functions including immune Checkpoint Systems by directly activating stress-responsive neurons</b>	10:15 - 10:15
<i>Speaker:</i> Kensuke Yamashita (Tokyo, Japan)	
<b>Investigating associations between BDNF, cortisol, and cognitive performance during psychosocial and heat stress</b>	10:15 - 10:15
<i>Speaker:</i> Jonathan Flintoff (Brisbane, Australia)	
<b>EL mouse as an animal model for epilepsy, anxiety and hyperactivity: involvement of Translocator Protein 18 kD (TSPO)</b>	10:15 - 10:15
<i>Speaker:</i> Yurie Nakamoto (Tokyo, Japan)	
<b>Effects of social jetlag on the different risk of anxiety between women and men: insights from the Taiwan biobank project</b>	10:15 - 10:15
<i>Speaker:</i> Min-Chiao Chang (Taipei, Taiwan)	
<b>Socioeconomic adversity, maternal nutrition, and the prenatal programming of child cognition and language at two years of age through maternal inflammation</b>	10:15 - 10:15
<i>Speaker:</i> Andrea Gogos (Parkville, Australia)	
<b>Psychosocial function and prescribed psychotropic medication in 269 Chinese adults with common mental disorders (CMD) over 9-year follow up</b>	10:15 - 10:15
<i>Speaker:</i> Linda CW Lam (Hong Kong, Hong Kong)	
<i>Special Format</i>	
10:50 - 11:50	PL
<b>Medical Legalization of Psychedelics: An International Perspective</b>	
<i>Chair:</i> Allan Young (London, United Kingdom)	
<b>Medical Legalization of Psychedelics: An International Perspective</b>	10:50 - 11:50
<i>Speaker:</i> Ilan Hayman (Melbourne, Australia)	
<i>Speaker:</i> Scott Edwards (Melbourne, Australia)	
<i>Speaker:</i> Lauren Macdonald (Melbourne, Australia)	
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)	
<i>Speaker:</i> Guy Goodwin (Oxford, United Kingdom)	

Symposium  
10:50 - 12:05 S1

**Symposium 8: From Molecular Mechanisms to Brain Circuitries: How Psychedelics are Reshaping Our Understanding of Neuropsychiatric and Behavioral Disorder Treatments**

Chair: Danilo De Gregorio (Milan, Italy)

**Molecular and cellular mechanisms of the long-lasting effects of psychedelics and their non-hallucinogenic derivatives** 10:50 - 11:15

Speaker: Argel Aguilar-Valles (Ottawa, Canada)

**Toward an understanding of the therapeutically relevant mechanisms of psilocybin for anorexia nervosa** 11:15 - 11:40

Speaker: Claire Foldi (Clayton, Australia)

**A single dose of lysergic acid diethylamide (LSD) reduces alcohol consumption and reverts dopaminergic (DA) dysfunction in male mice** 11:40 - 12:05

Speaker: Danilo De Gregorio (Milan, Italy)

Symposium  
10:50 - 12:05 S2

**Symposium 9: The Role of Biomarkers in The Development of More Personalized and Effective Treatments for Psychiatric Disorders**

Chair: Magdalene de Rozario (Melbourne, Australia)

**A systematic review of neuroimaging biomarkers to predict antipsychotic treatment response** 10:50 - 11:15

Speaker: Magdalene de Rozario (Melbourne, Australia)

**Inflammation and aging in psychosis - a transdiagnostic proteomics study using the Human Connectome Project for Early Psychosis (HCP-EP)** 11:15 - 11:40

Speaker: Moritz Haaf (Boston, United States)

**Biological aging indicators in stress-related disorders: a (neuro)biological perspective on lifestyle interventions in psychiatric practice** 11:40 - 12:05

Speaker: Laura Han (Amsterdam, Netherlands)

Symposium  
10:50 - 12:05 S3

**Symposium 7: Susceptibility in the Developing Brain: Why the Timing of Insults and Sex Matter**

Chair: Felipe Gomes (Ribeirao Preto, Brazil)

**Roles of dark microglia during development in health and maternal immune activation** 10:50 - 11:15

Speaker: Marie-Eve Tremblay (Victoria, Canada)

**Peripubertal stress exerts differential impacts on thalamic reticular and reuniens nuclei in male vs female rats** 11:15 - 11:40

Speaker: Anthony Grace (Pittsburgh, United States)

**The protective role of perineuronal nets against stress** 11:40 - 12:05

Speaker: Felipe Gomes (Ribeirao Preto, Brazil)

Data Blitz Session  
10:50 - 12:05 M1

**Data Blitz 4: Depression treatment**

Chair: Bernhard Baune (Münster, Germany)

**Effectiveness of transcranial pulse stimulation for major depression: preliminary evidence for clinical response and neuroimaging mechanisms** 10:50 - 10:56

Speaker: Penny Ping Qin (Hong Kong, Hong Kong)

**Association of TMS-induced cortical hemodynamic responses with relapse vulnerability in patients with major depressive disorder** 10:56 - 11:02

Speaker: Minxia Jin (Hong Kong, China)

**Patient and clinician acceptance of recent technological advances in the therapeutic monitoring of lithium** 11:02 - 11:08

Speaker: Seetal Dodd (Geelong, Australia)

**CT-152, a prescription digital therapeutic for Major depressive disorder: a real-world analysis of durability of treatment effect** 11:08 - 11:14

Speaker: Jeffrey Cochran (Princeton, United States)

**A Genetically Informed Approach to Antidepressant Prescription for Youth with Major Depressive Disorder** 11:14 - 11:20

Speaker: Bradley Roberts (Perth, Australia)

**Antidepressant activity of strategic electrical stimulation of prefrontocortical neurons primed for excitability** 11:20 - 11:26

Speaker: Francis Bambico (St. John's, Canada)

**Ethnic variability in rTMS dosage: A call for adaptive therapeutic innovation** 11:26 - 11:32

Speaker: Bella B.B. Zhang (Hung Hum, Hong Kong)

**A new chronic dizziness disease: persistent postural-perceptual dizziness (PPPD) and vortioxetine** 11:32 - 11:38

Speaker: Kensuke Kiyomizu (Nobeoka, Miyazaki, Japan)

**Discussion, Q&A** 11:38 - 12:05

*Selected Colloquium*

10:50 - 11:50

M2

**Selected Colloquium 9: Recent Advances in Obsessive Compulsive Disorder (OCD)**

Chair: Mohandas Warriar (Trichur, India)

**Circuits and Networks in OCD** 10:50 - 11:10

Speaker: Mohandas Warriar (Trichur, India)

**Evaluating OCD circuits with non-invasive neuromodulation: investigative and therapeutic studies** 11:10 - 11:30

Speaker: Janardhanan Narayanaswamy (Geelong, Australia)

**The 3S of pharmacological treatment for OCD (SRIs, super-doses, safety) - 2025 update** 11:30 - 11:50

Speaker: Joseph Zohar (Ramat Gan, Israel)

*Spotlight Session*

12:15 - 13:15

PL

**Spotlight Session 4: Women in Neuropsychopharmacology**

Chair: Gabriella Gobbi (Montreal, Canada)

Chair: Susan Shur-Fen Gau (Taipei, Taiwan)

**Women in Neuropsychopharmacology** 12:15 - 12:45

Speaker: Lianne Schmaal (Melbourne, Australia)

**Women in Neuropsychopharmacology: Discussion** 12:45 - 13:15

Speaker: Ya Mei Bai (Taipei, Taiwan)

Speaker: Lucie Bartova (Vienna, Austria)

Speaker: Kim Q. Do (Lausanne, Switzerland)

Speaker: Atsumi Nitta (Japan)

Speaker: Tian-Mei Si (Beijing, China)

<i>Featured Communication</i>		
12:15 - 13:15		S1
<b>Featured Communication 4: Schizophrenia/Clinical</b>		
<i>Chair:</i> Young-Chul Chung (Jeonju, Korea, Republic of)		
	<b>A population-based study on long-term mortality risk associated with clozapine use among patients with schizophrenia</b>	12:15 - 12:30
<i>Speaker:</i> Sherry Kit Wa Chan (Hong Kong, Hong Kong)		
	<b>Targeting microglial activation in schizophrenia: a longitudinal [18F]DPA-714 PET imaging study investigating the effects of a 3-month treatment with natalizumab - **Rafaelsen Young Investigators Award 2025**</b>	12:30 - 12:45
<i>Speaker:</i> Yuya Mizuno (London, United Kingdom)		
	<b>A novel graph theory-driven application of <sup>18</sup>F-FDG-PET with antipsychotic dose correction and a machine learning approach to capture discrete brain metabolic connectivity in treatment-resistant schizophrenia</b>	12:45 - 13:00
<i>Speaker:</i> Andrea de Bartolomeis (Napoli, Italy)		
	<b>Q&amp;A, Discussion</b>	13:00 - 13:15
 <i>Session</i>		
12:15 - 13:15		S2
<b>NbN Updates: NbN for patients &amp; families (NbNpf); Different Dose, Different Pharmacology concept (DDDP)</b>		
<i>Chair:</i> Joseph Zohar (Ramat Gan, Israel)		
	<b>Introduction and update on NbN in 2025</b>	12:15 - 12:30
<i>Speaker:</i> Joseph Zohar (Ramat Gan, Israel)		
	<b>Different Dose, Different Pharmacology (DDDP)</b>	12:30 - 12:45
<i>Speaker:</i> Pierre Blier (Ottawa, Canada)		
	<b>Challenges and opportunities in integrating serotonergic agonists ("psychedelics") into NbN</b>	12:45 - 13:00
<i>Speaker:</i> Guy Goodwin (Oxford, United Kingdom)		
	<b>Discussion and Q&amp;A</b>	13:00 - 13:15
<i>Speaker:</i> Hiroyuki Uchida (Japan)		
 <i>Selected Colloquium</i>		
12:15 - 13:15		S3
<b>Selected Colloquium 3: Targeting NMDA Receptors Mediate Neuron-Glia Interactions for the Treatment of Neuropsychiatric Disorders: From Basic Research to Application</b>		
<i>Chair:</i> Wen-Sung Lai (Taipei, Taiwan)		
	<b>Modulation of brain functions by glial reset</b>	12:15 - 12:35
<i>Speaker:</i> Schuichi Koizumi (Yamanashi, Japan)		
	<b>The role of glial phagocytosis in multiple sclerosis</b>	12:35 - 12:55
<i>Speaker:</i> Jungjoo Park (Daejeon, Korea, Republic of)		
	<b>Key molecules for neuron-glia Interactions during stress: Role of neurotransmitters</b>	12:55 - 13:15
<i>Speaker:</i> Tomoko Soga (Selangor Darul Ehsan, Malaysia)		
 <i>Data Blitz Session</i>		
12:15 - 13:15		M1
<b>Data Blitz 5: Psychedelic/ketamine-related</b>		
<i>Chair:</i> Argel Aguilar-Valles (Ottawa, Canada)		

<p><b>The mGluR2/3 antagonist enhances the behavioral and cellular antidepressant-like effects of psilocybin and scopolamine</b></p> <p><i>Speaker:</i> Andrzej Pilc (Krakow, Poland)</p>	<p>12:15 - 12:21</p>
<p><b>Mapping neuronal ensemble activity in the mouse prefrontal cortex during motivational control of behavior following ketamine treatment</b></p> <p><i>Speaker:</i> Jess Nithianantharajah (Parkville Victoria, Australia)</p>	<p>12:21 - 12:27</p>
<p><b>Psilocybin assisted psychotherapy for obsessive compulsive disorder, body dysmorphic disorder, and anorexia nervosa: study protocol</b></p> <p><i>Speaker:</i> Nicola Acevedo (Melbourne, Australia)</p>	<p>12:27 - 12:33</p>
<p><b>Elucidating NMDA Receptor Hypofunction using Simultaneous EEG-fMRI Measures of Ketamine-Induced Neural Dynamics</b></p> <p><i>Speaker:</i> Moritz Haaf (Boston, United States)</p>	<p>12:33 - 12:39</p>
<p><b>Psilocybin with Psychotherapeutic Support for Treatment-Resistant Depression: A Pilot Clinical Trial</b></p> <p><i>Speaker:</i> Sally Meikle (Melbourne, Australia)</p>	<p>12:39 - 12:45</p>
<p><b>Using Classification and Regression Tree Modelling to Investigate Low-Dose Ketamine's Effect on Remission of Suicidal Symptoms Among Patients with Treatment-Resistant Depression and Strong Suicidal Thought</b></p> <p><i>Speaker:</i> Ping Chung Wu (Taipei, Taiwan)</p>	<p>12:45 - 12:51</p>
<p><b>Therapeutic memory reconsolidation as a treatment for substance use disorders and how psychedelics are facilitating this intervention: The UNITY Study</b></p> <p><i>Speaker:</i> Shelan Ofori (London, United Kingdom)</p>	<p>12:51 - 12:57</p>
<p><b>Acute and chronic psilocybin in mouse models of psychiatric disorders</b></p> <p><i>Speaker:</i> Thibault Renoir (Melbourne, Australia)</p>	<p>12:57 - 13:03</p>
<p><b>Safety and ethical considerations for psychedelic assisted psychotherapy (PAP)</b></p> <p><i>Speaker:</i> Susan Rossell (Melbourne, Australia)</p>	<p>13:03 - 13:09</p>
<p><b>Discussion, Q&amp;A</b></p>	<p>13:09 - 13:15</p>
<p><i>Selected Colloquium</i></p>	
<p>12:15 - 13:15</p> <p><b>Selected Colloquium 8: Lithium: the latest news about the oldest drug in psychiatry</b></p> <p><i>Chair:</i> Marylou Selo (New York, United States)</p>	<p>M2</p>
<p><b>"Getting old on the oldest drug" Ticking on Lithium Batteries for 45 years</b></p> <p><i>Speaker:</i> Marylou Selo (New York, United States)</p>	<p>12:15 - 12:35</p>
<p><b>The eyes have it - lithium and neuroprotection in the brain and beyond</b></p> <p><i>Speaker:</i> Janusz Rybakowski (Poznan, Poland)</p>	<p>12:35 - 12:55</p>
<p><b>Lithium: how low could we go?</b></p> <p><i>Speaker:</i> Allan Young (London, United Kingdom)</p>	<p>12:55 - 13:15</p>
<p><i>Break</i></p>	
<p>13:15 - 14:40</p> <p><b>Lunch Break</b></p>	<p>SR</p>
<p><b>Test Confirmation</b></p>	<p>13:15 - 13:25</p>

Speaker: Oswin Lohne (Hann, Germany)

*Sponsored Symposium*

13:25 - 14:25

S1

**Sponsored Lunch Symposium**

*Posters*

13:25 - 13:55

EXH

**Poster Session 4: Childhood & Adolescent Disorders, ADHD, Dementia, Epilepsy, Pain, Variable**

Chair: Lianne Schmaal (Melbourne, Australia)

**Role of the anterior insula and the endocannabinoid system in Autism neurodevelopmental disorder**

13:25 - 13:25

Speaker: Elena Martín García (Barcelona, Spain)

**Therapeutic potential of low-dose opioids through brain region-specific neural activation for autism spectrum disorder**

13:25 - 13:25

Speaker: Rei Yokoyama (Hiroshima, Japan)

**Developmental inhibition of Purkinje cells causes male-specific ASD-like phenotypes - vulnerable male cerebellum hypothesis**

13:25 - 13:25

Speaker: Satoshi Kamiyo (Tokyo, Japan)

**$\alpha 6$ GABA<sub>A</sub> receptor-selective positive allosteric modulator as a potential therapy for autism: A preclinical study in Fmr1 KO mice**

13:25 - 13:25

Speaker: Yu-Hsuan Lee (Taipei, Taiwan)

**A Genome-Wide Association Study of Autistic Traits and Neurocognitive Function in Autism**

13:25 - 13:25

**Effects of low dose valproic acid on sleep disorders in autism spectrum disorder**

13:25 - 13:25

Speaker: Eiji Nakagawa (Tokyo, Japan)

**The Relationship Between Genetic Liability of Autism Associated Co-Occurring Conditions and Clinical Severity and Neurocognitive Function in Autism**

13:25 - 13:25

**Does prenatal exposure to low-dose di-2-ethylhexyl phthalate impair neurodevelopment in a Val66Met BDNF mouse model?**

13:25 - 13:25

Speaker: Alicia Bjorksten (Melbourne, Australia)

**A Novel Diathesis-Stress Model of Commonly Comorbid Early Onset Psychiatric Disorders**

13:25 - 13:25

Speaker: Charlotte Caswell (Montreal, Canada)

**Role of attention deficit hyperactivity disorder and major depressive disorder on executive dysfunction and appetite hormone dysregulation and proinflammatory cytokines among adolescents with death ideation**

13:25 - 13:25

Speaker: Jia Shyun Jeng (Taipei, Taiwan)

**Cannabidiol mitigates cognitive deficits in a mouse model of Alzheimer's disease**

13:25 - 13:25

Speaker: Yi-Chia Chen (Tainan, Taiwan)

**RX 821002, an alpha2 adrenoceptor antagonist, enhances acetylcholine efflux in the nucleus accumbens of freely moving rats following intra-accumbal and systemic administration**

13:25 - 13:25

Speaker: Kazuki Arai (Chiba, Japan)

**Cannabigerol Reduces Neurodegeneration and Attenuates Glial Response in the Hippocampus of Mice with Transient Global Cerebral Ischemia**

13:25 - 13:25

<p><b>Protective effects of Shati/Nat8l on A<math>\beta</math> neurotoxicity in the cultured Neuro-2a cells</b></p> <p><i>Speaker:</i> Miho Takakuwa (Toyama City, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>Decreased brain pH correlated with progression of Alzheimer's disease neuropathology: a systematic review and meta-analyses of postmortem studies</b></p> <p><i>Speaker:</i> Hideo Hagihara (Toyoake, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>Cognitive flexibility as a possible index of age-related cognitive decline</b></p> <p><i>Speaker:</i> Masaki Kakeyama (Tokorozawa, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>Genome-wide association study of frailty in middle-aged adults: insights from ZNF552 rs2288538 variant</b></p> <p><i>Speaker:</i> Tung-Hsia Liu (Miaoli County, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Glycosylation modifications correlating with plasma CCL11 elevation in patients with moderate dementia</b></p> <p><i>Speaker:</i> Yu-Li Liu (Miaoli County, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Effects of 24-month supplementation of EPA and dha on hippocampal spontaneous neuroactivity in mild cognitive impairment and dementia: a resting-state fMRI study</b></p> <p><i>Speaker:</i> Chen-Chia Lan (Taichung, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Theoretical drug selection for BPSD</b></p> <p><i>Speaker:</i> Shuji Iritani (Toyoake, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>Unveiling the Cognitive Enhancing Effects of RS-D7, a Novel NMDAR Modulator, on Hippocampus-Dependent Learning and Memory in Mice</b></p> <p><i>Speaker:</i> Hsin-Ching Chien (Taipei, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Toxicity and metabolism of structurally similar fentanyl analogs with the integrated approach using <i>in vitro</i> experiments and <i>in silico</i> predictions</b></p> <p><i>Speaker:</i> Ryo Hiramasa (Gifu, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>The development of AUFEL: culture-centered executive function measurement tools for Indonesian children and adolescents</b></p> <p><i>Speaker:</i> Suzy Yusna Dewi (Jakarta, Indonesia)</p>	<p>13:25 - 13:25</p>
<p><b>Changes in decision making behavior between pregnancy and postpartum</b></p> <p><i>Speaker:</i> M. Mercedes Perez-Rodriguez (New York, United States)</p>	<p>13:25 - 13:25</p>
<p><b>Exploring the Association Between Prenatal SARS-CoV-2 Infection, Placental Immune and Inflammatory Gene Expression and Postpartum Depression with a Validation Analysis</b></p> <p><i>Speaker:</i> M. Mercedes Perez-Rodriguez (New York, United States)</p>	<p>13:25 - 13:25</p>
<p><b>The role of neutrophil myeloperoxidase and the neuronal injury marker neurofilament light chain in COVID-19 infected patients</b></p> <p><i>Speaker:</i> Shu Chih Liu (Miaoli, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Regulatory mechanism of astrocytic glutamine synthetase expression in epileptic brain via Hippo-YAP pathway</b></p> <p><i>Speaker:</i> Yusuke Nasu (Niigata, Japan)</p>	<p>13:25 - 13:25</p>
<p><b>The role of ANT in modulating hippocampal oscillations in animal models of epilepsy</b></p> <p><i>Speaker:</i> Yu-Chieh Huang (Tainan, Taiwan)</p>	<p>13:25 - 13:25</p>
<p><b>Are Persistent Somatic Symptoms a Trans-Diagnostic Concept? A cluster analysis</b></p>	<p>13:25 - 13:25</p>

<i>Speaker:</i> Wei-Lieh Huang (Douliu, Taiwan)		
	<b>The relieving effect of activating the pleasure center VTA on chronic stress-induced hyperalgesia</b>	13:25 - 13:25
<i>Speaker:</i> An-Chi Hsu (Tainan, Taiwan)		
	<b>Effect of cannabinoid CB2 agonist on cold hypersensitivity in mice with post-traumatic trigeminal neuropathy</b>	13:25 - 13:25
<i>Speaker:</i> Simeng Ma (Hiroshima, Japan)		
	<b>Enhancement of <i>in vivo</i> dopamine efflux in the rat nucleus accumbens by orexin OX<sub>2</sub> receptor blockade is reduced in two chronic pain models</b>	13:25 - 13:25
<i>Speaker:</i> Tadashi Saigusa (Matsudo, Japan)		
	<b>Glutamate, glutamine, and GABA levels in adults with autism spectrum disorder: a 7T MRS study</b>	13:25 - 13:25
<i>Speaker:</i> Manabu Kubota (Chiba, Japan)		
	<b>Exploring the dynamics of L1 retrotransposition in natural aging: Insights from the mouse model</b>	13:25 - 13:25
<i>Speaker:</i> Chu Guo (Kumamoto, Japan)		
	<b>Neuropsychiatric symptoms as predictors for cognitive impairment and revert factors for normal cognition: a one-year prospective cohort study</b>	13:25 - 13:25
<i>Speaker:</i> Daochompu Nakawiro (Bangkok, Thailand)		
	<b>DNMT1 complex disorders: neurodegeneration from a specific DNA methylation defect. The mutation knock in mouse model present similar to clinical form of HSN1E</b>	13:25 - 13:25
<i>Speaker:</i> Kaori Hojo (Hyogo Prefect, Japan)		
<i>Posters</i>		
13:55 - 14:25		EXH
<b>Poster Session 5: Depression</b>		
<i>Chair:</i> Pierre Blier (Ottawa, Canada)		
	<b>M6A-mediated epitranscriptomic modifications in depression</b>	13:55 - 13:55
<i>Speaker:</i> Yogesh Dwivedi (Birmingham, United States)		
	<b>Differential effects of Psilocybin and Lisuride on Serotonin and Dopamine neuronal activity and behavior</b>	13:55 - 13:55
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)		
	<b>L655,708 a negative allosteric modulator at of GABA<sub>A</sub> receptor increased dopamine neuronal activity up to 1 week after a single injection</b>	13:55 - 13:55
<i>Speaker:</i> Pierre Blier (Ottawa, Canada)		
	<b>The inhibitory effect of ifenprodil on nicotine-induced addictive behaviors</b>	13:55 - 13:55
<i>Speaker:</i> Soichiro Ide (Tokyo, Japan)		
	<b>Increase of the AMPA-evoked response in prefrontal cortex pyramidal neurons following acute administration of ketamine and S-ketamine in rats</b>	13:55 - 13:55
<i>Speaker:</i> Pierre Blier (Ottawa, Canada)		
	<b>5-HT<sub>2B</sub> receptors modulate the antidepressant-like response of the psychedelic LSD in rat but not in mice</b>	13:55 - 13:55
<i>Speaker:</i> Nasser Haddjeri (Bron, France)		
	<b>Using the live rat stress paradigm to investigate approach-avoidance behaviour relevant to psychiatric disorders</b>	13:55 - 13:55

<i>Speaker:</i> Jacqueline Iredale (Newcastle, Australia)		
	<b>Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression</b>	13:55 - 13:55
<i>Speaker:</i> Nicole Silva (Aarhus, Denmark)		
	<b>Knockdown of connexin43 in astrocytes is involved in the therapeutic effect of tricyclic antidepressant amitriptyline</b>	13:55 - 13:55
<i>Speaker:</i> Nozomi Tokunaga (Hiroshima, Japan)		
	<b>Discovering markers of intron retention in depression and its response to ketamine</b>	13:55 - 13:55
<i>Speaker:</i> Norihiro Okada (Tokyo, Japan)		
	<b>Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the triple reuptake inhibitor JS1-1-01 to determine the recommended phase II dose</b>	13:55 - 13:55
<i>Speaker:</i> Zhiwei Huang (Shanghai, China)		
	<b>Common and distinct effects of 10-hz rTMS and iTBS on striatum-based functional connectivity in major depressive disorder: a sham-controlled study</b>	13:55 - 13:55
<i>Speaker:</i> Cheng-Ta Li (Taipei, Taiwan)		
	<b>Anxiety behavior and immune response of microglia in rats subjected to stress through the sympathetic nervous system</b>	13:55 - 13:55
<i>Speaker:</i> Akihito Uezato (Tochigi, Japan)		
	<b>The Role of Gut Microbiome Levels in Depressive Disorder as a Psychological Indicator A Systematic Review for Malnutrition Prevention and Increased Risk of Metabolic Diseases</b>	13:55 - 13:55
	<b>A multicenter clinical trial of Shuganjiyu capsules combined with Fluoxetine in the treatment of depression</b>	13:55 - 13:55
<i>Speaker:</i> Jitao Li (Beijing, China)		
	<b>Development of metabolomic biomarker signatures and diagnostic models for major depressive disorder using multiple supervised learning methods</b>	13:55 - 13:55
<i>Speaker:</i> Shen He (Shanghai, China)		
	<b>Exploring the subjective experience of patients with treatment-resistant depression on the effects of Esketamine Nasal Spray</b>	13:55 - 13:55
<i>Speaker:</i> Giovanni Martinotti (Chieti, Italy)		
	<b>Effects of low-dose naltrexone on salience network connectivity in major depressive disorder</b>	13:55 - 13:55
<i>Speaker:</i> Ben Moloney (Auckland, New Zealand)		
	<b>Does Excitatory/Inhibitory Balance Predict Ketamine Response in Treatment-Resistant Depression?: A Double-Blind Randomized Controlled Trial with <sup>1</sup>H-MRS</b>	13:55 - 13:55
<i>Speaker:</i> Yohei Ohtani (Tokyo, Japan)		
	<b>Age-specific variations in antidepressant efficacy of transcranial magnetic stimulation for treatment-resistant depression: a real-world retrospective study</b>	13:55 - 13:55
<i>Speaker:</i> Jia Shyun Jeng (Taipei, Taiwan)		
	<b>Longitudinal follow-up study of mood symptom rating, suicidality, psychological and physical health and quality of life post-rTMS in the refractory depressed patients in Taiwan</b>	13:55 - 13:55
<i>Speaker:</i> Tung-Ping Su (Taipei, Taiwan)		
	<b>The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: a</b>	13:55 - 13:55

<b>52-Week double-blind, placebo-controlled trial</b>		
<i>Speaker:</i> Yingchih Cheng (Zhubei City, Taiwan)		
<b>Predicting rTMS treatment response in depression: use of machine learning models to identify the roles of metabolic and clinical factors</b>	13:55 - 13:55	
<i>Speaker:</i> I Chun Liu (Tainan City, Taiwan)		
<b>Screening and diagnosis of depression: Correlation of genomic alterations with functional magnetic resonance imaging</b>	13:55 - 13:55	
<i>Speaker:</i> Paramdeep Singh (Bathinda, India)		
<b>Optimizing rTMS for depressive disorders: comparative efficacy and insights into clinical factors</b>	13:55 - 13:55	
<i>Speaker:</i> Chia-Hao Ma (Douliu City, Taiwan)		
<b>Mapping peripheral molecular mechanisms associated with long-lasting effects of early life stress: a transcriptomic set-based approach</b>	13:55 - 13:55	
<i>Speaker:</i> Chiara Bottanelli (Milan, Italy)		
<b>Clinical experiences with esketamine treatment at the department of psychiatry and psychological medicine, University Hospital Centre Zagreb, during the period from 2022 to 2024</b>	13:55 - 13:55	
<i>Speaker:</i> Maja Živković (Zagreb, Croatia)		
<b>Association between endocrine disruptors and depressive symptoms among Taiwanese adolescents</b>	13:55 - 13:55	
<i>Speaker:</i> Yu-Hsin Huang (Taipei, Taiwan)		
<b>Toward effective speech-based depression recognition: investigating data balance and depressive symptom severity in AI approaches</b>	13:55 - 13:55	
<i>Speaker:</i> Min Jhon (Gwangju, Korea, Republic of)		
<b>Renin-angiotensin system in patients with major depressive disorder</b>	13:55 - 13:55	
<i>Speaker:</i> Chun-Hsin Chen (Taipei, Taiwan)		
<b>Exploring LSD Microdosing in an open-label pilot for Major Depressive Disorder: The Interplay of Behavioral Activation, Mood Improvement, and Connectedness</b>	13:55 - 13:55	
<i>Speaker:</i> Carina Donegan (Auckland, New Zealand)		
<b>Beyond the hype: examining the therapeutic potential of psychedelic microdosing through the lens of experimental control and evidence</b>	13:55 - 13:55	
<i>Speaker:</i> Orla Mallon (London, United Kingdom)		
<b>Neural and behavioral evidence from reinforcement learning converge in support of relaxed beliefs under LSD</b>	13:55 - 13:55	
<i>Speaker:</i> Jonathan Kanen (New York, United States)		
<b>Altered cerebral TSPO availability and functional connectivity in patients with major depressive disorder: a preliminary multimodal imaging study combining C-11 PK11195 PET and rs-fMRI</b>	13:55 - 13:55	
<i>Speaker:</i> Jong-Hoon Kim (Incheon, Korea, Republic of)		
<b>Resting-state functional connectivity associations with suicidal ideation severity in treatment-resistant depression</b>	13:55 - 13:55	
<i>Speaker:</i> Patricia Burhunduli (Ottawa, Canada)		
<b>Antidepressant use and antibiotics treatment failure</b>	13:55 - 13:55	
<i>Speaker:</i> Chi-Shin Wu (Zhunan, Taiwan)		
<b>Optimizing sham control in transcutaneous auricular vagus nerve</b>	13:55 - 13:55	

**stimulation for chronic insomnia: a pooled analysis from two randomized clinical studies**

Speaker: Zongshi Qin (Beijing, China)

*Symposium*

14:40 - 15:55

PL

**Symposium 10: Adversity and altered states? The neurobiological signature of early life adversity on the brain, and relevance to psychoactive drug responses**

Chair: Molly Carlyle (Oslo, Norway)

**Lifetime neural circuit and behavioral disruptions in a mouse model of childhood abuse**

14:40 - 15:05

Speaker: Erin Hisey (Boston, United States)

**Impacts of early life adversity on drug effects in healthy controls and substance use groups using acute and retrospective drug responses.**

15:05 - 15:30

Speaker: Molly Carlyle (Oslo, Norway)

**Differing responses to ketamine and MDMA in patients with and without early adversity: integrating clinical trial and naturalistic drug user findings**

15:30 - 15:55

Speaker: Celia J.A. Morgan (Exeter, United Kingdom)

*Symposium*

14:40 - 15:55

S1

**Symposium 11: Adult neurogenesis or de-differentiation regulate hippocampus plasticity in health and disease**

Chair: Maura Boldrini (New York, United States)

**A Baldwin interpretation of adult hippocampal neurogenesis: from functional relevance to pathophysiology**

14:40 - 15:05

Speaker: Djoher Nora Arous (Bordeaux Cedex, France)

**Repetitive neuronal activations regulate cellular maturation state via nuclear reprogramming**

15:05 - 15:30

Speaker: Tsuyoshi Miyakawa (Toyoake, Japan)

**Molecular landscapes of hippocampal neurogenesis are disrupted in major depression**

15:30 - 15:55

Speaker: Maura Boldrini (New York, United States)

*Symposium*

14:40 - 15:55

S2

**Symposium 12: Reformulation, omics-based biomarkers and health economic implications of ketamine in the treatment of depression**

Chair: Bernhard Baune (Münster, Germany)

**Expanding access to ketamine through reformulation**

14:40 - 15:05

Speaker: Paul Glue (Otago, New Zealand)

**Discovery of omics-biomarkers of ketamine for treatment response in depression**

15:05 - 15:30

Speaker: Bernhard Baune (Münster, Germany)

**Economic evaluations of emerging pharmacological therapies for treatment resistant depression**

15:30 - 15:55

Speaker: Mary Lou Chatterton (Melbourne, Australia)

*Meet the Experts / Campfire Session*

14:40 - 15:40

S3

**Campfire Session: I Was So Much Older Then: Reflections on Research for Early Career Researchers (LIMITED SEATS)**

*Chair:* Allan Young (London, United Kingdom)

**I Was So Much Older Then: Reflections on Research for Early Career Researchers**

14:40 - 15:40

*Speaker:* Allan Young (London, United Kingdom)

*Speaker:* Gabriella Gobbi (Montreal, Canada)

*Speaker:* Michael Berk (Geelong, Australia)

*Selected Colloquium*

14:40 - 15:40

M1

**Selected Colloquium 4: Circuits driving drug taking: What insights for treatment do they hold?**

*Chair:* Jacqueline Iredale (Newcastle, Australia)

**A master regulator of opioid reward in the ventral prefrontal cortex**

14:40 - 15:00

*Speaker:* Paul Kenny (New York, United States)

**Sex differences in neural circuits driving binge drinking**

15:00 - 15:20

*Speaker:* Leigh Walker (Melbourne, Australia)

**Targeting the orexin (hypocretin) system to normalize sleep disturbances during cocaine abstinence**

15:20 - 15:40

*Speaker:* Morgan H. James (Camperdown, Australia)

*Spotlight Session*

14:40 - 15:40

M2

**Spotlight Session 5: Addiction and Mental Health**

*Chair:* Marco Leyton (Montreal, Canada)

**Addictions and Mental Health**

14:40 - 15:10

*Speaker:* Marco Leyton (Montreal, Canada)

**Discussion on Addictions**

15:10 - 15:40

*Speaker:* Guy Goodwin (Oxford, United Kingdom)

*Speaker:* Antonio Verdejo-Garcia (Melbourne, Australia)

*Speaker:* Marco Leyton (Montreal, Canada)

*Speaker:* Leah Mayo (Calgary, Canada)

*Break*

15:55 - 16:35

SR

**Afternoon Coffee Break**

*Featured Communication*

16:35 - 17:35

PL

**Featured Communication 5: Addiction/Cannabis**

*Chair:* Ming-Chyi Huang (Taipei, Taiwan)

**Pharmaco-omics of acamprosate treatment response: from clinical trial to biomarker discovery**

16:35 - 16:50

*Speaker:* Ming-Fen Ho (Rochester, United States)

**Insulin-like growth factor 1 in the brain and addiction --- the vulnerable prefrontal cortex in opioid use disorder - \*\*Rafaelsen Young Investigators Award 2025\*\***

16:50 - 17:05

*Speaker:* Zi-Jun Wang (Lawrence, United States)

**The Effects of Extended Cannabis Abstinence in Young Adults with Co-Occurring Cannabis Use Disorder and Major Depression**

17:05 - 17:20

*Speaker:* Tony George (Toronto, Canada)

<b>The effect of adolescent pre-treatment with the selective Cannabinoid 1 receptor agonist on hippocampal theta synchronization in adulthood</b>	17:20 - 17:35
<i>Speaker:</i> Bernat Kocsis (Boston, United States)	
 <i>Spotlight Session</i> 16:35 - 17:35	
S1	
<b>Spotlight Session 7: Frontiers of schizophrenia research in basic and clinical from JSNP and JSCNP</b>	
<i>Chair:</i> Atsumi Nitta (Japan)	
<b>Dopamine and Glutamate Hypotheses for Treatment Response in Schizophrenia</b>	16:35 - 16:55
<i>Speaker:</i> Yumina Nakane (Japan)	
<b>Frontotemporal Network Deficits and Auditory Impairments of EGF-induced Animal Model for Schizophrenia</b>	16:55 - 17:15
<i>Speaker:</i> Hiroyuki Nawa (Wakayama, Japan)	
<b>Mouse Phenotype-Driven Approach to Schizophrenia Research</b>	17:15 - 17:35
<i>Speaker:</i> Takao Keizo (Japan)	
 <i>Spotlight Session</i> 16:35 - 17:35	
S2	
<b>Spotlight Session 8: Recent advances in Alzheimer's Disease</b>	
<i>Chair:</i> Anya Topiwala (Oxford, United Kingdom)	
<b>Immuno-therapies for Alzheimer's disease work best in the earliest stages: prospects for primary and secondary prevention</b>	16:35 - 17:05
<i>Speaker:</i> Colin Masters (Australia)	
<b>Pharmacological Properties of Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease</b>	17:05 - 17:35
<i>Speaker:</i> Tetsuro Kikuchi (Japan)	
 <i>Spotlight Session</i> 16:35 - 17:35	
S3	
<b>Spotlight Session 6: Between Passion and Pressure: Early Career Researchers Round Table</b>	
<i>Chair:</i> Gabriella Gobbi (Montreal, Canada)	
<b>Early Career Researchers Round Table</b>	16:35 - 17:35
<i>Speaker:</i> Gabriella Gobbi (Montreal, Canada)	
<i>Speaker:</i> Lucie Bartova (Vienna, Austria)	
<i>Speaker:</i> Diego A. Pizzagalli (Belmont, United States)	
<i>Speaker:</i> Maria Teresa Ferretti (Klosterneuburg, Austria)	
<i>Speaker:</i> Pornjira Pariwatcharakul (Bangkok, Thailand)	
 <i>Data Blitz Session</i> 16:35 - 17:35	
M1	
<b>Data Blitz 6: Psychosis characterization</b>	
<i>Chair:</i> Kiyoyuki Kitaichi (Gifu, Japan)	
<b>Shorter Telomere Length in Schizophrenia Patients Compared to Healthy Controls, Independent of Treatment, Psychotic Status, and Metabolic Factors</b>	16:35 - 16:41
<i>Speaker:</i> Pin-Wen Lai (Taipei, Taiwan)	
<b>Haematological and inflammatory markers associated with non-remission and treatment resistance in schizophrenia</b>	16:41 - 16:47
<i>Speaker:</i> Yanhui Li (Singapore, Singapore)	
<b>Feature selection and algorithm optimization for Brain age</b>	16:47 - 16:53

**prediction in schizophrenia patients**

*Speaker:* Yen-Wei Chu (Taichung City, Taiwan)

**Revealing novel biomarkers and therapeutic targets Gene in schizophrenia a bioinformatic study through protein-protein interaction network analysis** 16:53 - 16:59

*Speaker:* Adicitra Auriel Bestari (Surabaya, Indonesia)

**Psychiatric comorbidity in patients with tinnitus or auditory hallucination and sleep evaluation, sound therapy and Shared Decision Making (SDM)** 16:59 - 17:05

*Speaker:* Kensuke Kiyomizu (Nobeoka, Miyazaki, Japan)

**To explore the effect of psychophysiological markers for stress regulation in patients with schizophrenia: an implication of cardiovascular risk** 17:05 - 17:11

*Speaker:* Yu-Wei Lin (Taichung, Taiwan)

**Clinical features and neural substrates underlying humor processing in patients with first episode schizophrenia** 17:11 - 17:17

*Speaker:* Bingjie Huang (Beijing, China)

**Prebiotics rescue gut microbiome dysregulation and enhance cognitive and gastrointestinal function in a mouse model of schizophrenia** 17:17 - 17:23

*Speaker:* Anthony J. Hannan (Parkville, Australia)

**Elevated levels of AKT-interacting protein in the frontal pole reveals molecular pathology specific to a subtype of people with schizophrenia** 17:23 - 17:29

*Speaker:* Megan Snelleks (Melbourne, Australia)

**Role of cognitive function in functional outcome in psychotic and affective inpatients** 17:29 - 17:35

*Speaker:* Gabriele Sachs (Vienna, Austria)

*Posters*

16:35 - 17:35

M2

**Outstanding Poster Presentation Session**

*Chair:* Rachel Hill (Clayton, Australia)

**Outstanding Poster Presentation Session: During the first days of the congress there will be a voting for posters available via the congress app. The 6 presenters with the most votes will have the opportunity to present their work in a 10 min talk during the "Outstanding Poster Presentation Session". We encourage all participants to support their peers by voting.** 16:35 - 17:35

*Spotlight Session*

17:40 - 18:40

PL

**Spotlight Session 9: Recent Advances in ADHD**

*Chair:* Yu-Ming Chen (Taipei, Taiwan)

**Recent Advances in ADHD** 17:40 - 18:10

*Speaker:* Susan Shur-Fen Gau (Taipei, Taiwan)

**Recent Advances in ADHD 2** 18:10 - 18:40

*Speaker:* David Coghill (Australia)

<i>Featured Communication</i>		
17:40 - 18:40		S1
<b>Featured Communication 6: Steroids/Depression</b>		
<i>Chair:</i> Hideki Miwa (Tokyo, Japan)		
	<b>Involvement of the gut-brain axis in food addiction</b>	17:40 - 17:55
<i>Speaker:</i> Rafael Maldonado (Barcelona, Spain)		
	<b>Increased sensitivity of central serotonergic neurons to corticosteroids following maternal immune activation: significance for mood disorders</b>	17:55 - 18:10
<i>Speaker:</i> Eliyahu Dremencov (Bratislava, Slovakia)		
	<b>Antidepressants interact with the components of sex steroid receptors</b>	18:10 - 18:25
<i>Speaker:</i> Shokouh Arjmand (Aarhus, Denmark)		
	<b>Differential Gene expression involving the epidermal growth factor (EGF) and immune system pathways in dorsolateral prefrontal (BA46) and orbitofrontal (BA11) cortical regions in mood disorders</b>	18:25 - 18:40
<i>Speaker:</i> Tharini Ketharanathan (Parkville, Australia)		
 <i>Data Blitz Session</i>		
17:40 - 18:40		S2
<b>Data Blitz 7: Schizophrenia-related</b>		
<i>Chair:</i> Yukiori Goto (Kyoto, Japan)		
	<b>Organizing the disorganization: an artificial intelligence-based decision supporting system for the detection of disorganization symptoms in schizophrenia and non-affected participants</b>	17:40 - 17:46
<i>Speaker:</i> Felice Iasevoli (Naples, Italy)		
	<b>Differences in Changes of Peptide Antigen-Related Antibody Levels Between Remission and Non-Remission Groups After One Year of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients</b>	17:46 - 17:52
<i>Speaker:</i> Yue Zheng (Beijing, China)		
	<b>The association between brown adipose tissue (BAT)-brain axis activity and the risk of metabolic adversities in patients with schizophrenia treated with antipsychotic drugs (APDs)</b>	17:52 - 17:58
<i>Speaker:</i> Po-Yu Chen (Taipei, Taiwan)		
	<b>Oxytocin as a potential biomarker for metabolic syndrome in schizophrenia</b>	17:58 - 18:04
<i>Speaker:</i> Kah Kheng Goh (Taipei City, Taiwan)		
	<b>Effects of GLT-1 modulator, MC-100093, on neuroinflammatory factor in mesocorticolimbic brain regions of female P rats exposed chronically to ethanol</b>	18:04 - 18:10
<i>Speaker:</i> Youssef Sari (Toledo, United States)		
	<b>Neurophysiological insights into omission mismatch negativity: Evidence from macro calcium imaging in rat auditory cortex</b>	18:10 - 18:16
<i>Speaker:</i> Hiroyuki Nawa (Wakayama, Japan)		
	<b>The association between obstructive sleep apnea and psychiatric disorders: a population-based risk analysis</b>	18:16 - 18:22
<i>Speaker:</i> Chuan-Yi Kao (Taichung, Taiwan)		
	<b>Mice carrying the Arx<sup>R264Q</sup> mutation show sex-specific disruptions to parvalbumin and somatostatin interneuron densities</b>	18:22 - 18:28
<i>Speaker:</i> Victoria Edwards-Poulton (Clayton, Australia)		
	<b>Discussion, Q&amp;A</b>	18:28 - 18:40

Session  
17:40 - 18:40 S3

**CINP General Assembly: CINP Members only**

Selected Colloquium  
17:40 - 18:40 M1

**Selected Colloquium 1: Effects of Early Life Adversity on the Structure of Common Mental Disorders: Reimagining the Diathesis-Stress Model**

Chair: Kim Felmingham (Melbourne, Australia)

**Connecting the transdiagnostic internalizing spectrum with epigenetic aging: a HiTOP approach** 17:40 - 18:00

Speaker: Robert Krueger (Minneapolis, United States)

**Measuring the accumulation of psychosocial stressors** 18:00 - 18:20

Speaker: Frank Mann (Stony Brook, United States)

**Reimagining the diathesis-stress model: transdiagnostic factors to precision psychiatry** 18:20 - 18:40

Speaker: Marco Leyton (Montreal, Canada)

Selected Colloquium  
17:40 - 18:40 M2

**Selected Colloquium 7: Re-Evaluating 'Older' Drugs for the Treatment of Mood Disorders; a Focus on MAOI's, Lithium and Psychedelics**

Chair: Allan Young (London, United Kingdom)

**Psychedelics: current state and future prospects** 17:40 - 18:00

Speaker: Allan Young (London, United Kingdom)

**MAOIs: efficacy, tolerability and acceptability of MAOI's for the treatment of mood disorders** 18:00 - 18:20

Speaker: Paul Stokes (London, United Kingdom)

**Lithium: from Cade to the modern day** 18:20 - 18:40

Speaker: Janusz Rybakowski (Poznan, Poland)

Networking  
18:40 - 20:00 SR

**CINP Members' Reception**

**Wednesday, 18. June 2025**

<i>Plenary</i>		
09:10 - 10:10		PL
<b>Plenary 5: Keynote Lecture Patrick McGorry</b>		
<i>Chair:</i> Kim Q. Do (Lausanne, Switzerland)		
<i>Chair:</i> Tian-Mei Si (Beijing, China)		
<b>The Global Youth Mental Health Crisis: Megatrends and Solutions</b>	09:10 - 10:10	
<i>Speaker:</i> Patrick McGorry (Parkville, Australia)		
<i>Networking</i>		
09:30 - 16:45		SR
<b>OPEN: Exhibition &amp; CINP Members' Lounge</b>		
<i>Break</i>		
10:10 - 10:50		SR
<b>Morning Coffee Break</b>		
<i>Symposium</i>		
10:50 - 12:05		PL
<b>Symposium 13: Modulating the brain with light, sound and electric fields - the future of non-invasive brain stimulation in psychiatry?</b>		
<i>Chair:</i> Lucie Bartova (Vienna, Austria)		
<i>Chair:</i> Georg Kranz (Hogn Kong, Hong Kong)		
<b>Transcranial magnetic stimulation in less common indications - focused on schizophrenia and borderline personality disorder</b>	10:50 - 11:15	
<i>Speaker:</i> Libor Ustohal (Brno, Czech Republic)		
<b>Research on Transcranial Pulse Stimulation (TPS) in Major Depressive Disorder (MDD)</b>	11:15 - 11:40	
<i>Speaker:</i> Georg Kranz (Hogn Kong, Hong Kong)		
<b>The use of intermittent light at 60Hz for brain entrainment and its effect on neuroplasticity in mice and modulation of EEG patterns in healthy humans</b>	11:40 - 12:05	
<i>Speaker:</i> Maria Teresa Ferretti (Klosterneuburg, Austria)		
<i>Symposium</i>		
10:50 - 12:05		S1
<b>Symposium 14: Genetic Insights into Individual Variability in the Effects of Addictive Substances</b>		
<i>Chair:</i> Kazutaka Ikeda (Tokyo, Japan)		
<b>Genetic insights into cannabis use and use disorder.</b>	10:50 - 11:15	
<i>Speaker:</i> Joel Gelernter (West Haven, United States)		
<b>The role of alcohol in dementia</b>	11:15 - 11:40	
<i>Speaker:</i> Anya Topiwala (Oxford, United Kingdom)		
<b>Genetic polymorphisms associated with opioid sensitivity in patients undergoing palliative care and general anaesthesia</b>	11:40 - 12:05	
<i>Speaker:</i> Daisuke Nishizawa (Tokyo, Japan)		
<i>Symposium</i>		
10:50 - 12:05		S2
<b>Symposium 15: Neural Circuits of Dorsal Striatum and Amygdala in Addictive Behaviors</b>		
<i>Chair:</i> Doo-Sup Choi (Rochester, United States)		

<p><b>Indirect medium spiny neurons in the dorsolateral striatum projecting to the external globus pallidus regulate compulsive alcohol-seeking behaviors</b></p> <p><i>Speaker:</i> Doo-Sup Choi (Rochester, United States)</p>	<p>10:50 - 11:15</p>
<p><b>The circuit basis of cocaine-induced orofacial stereotypies</b></p> <p><i>Speaker:</i> Ami Citri (Jerusalem, Israel)</p>	<p>11:15 - 11:40</p>
<p><b>Dopaminergic control of compulsive eating</b></p> <p><i>Speaker:</i> Ja-Hyun Baik (Seoul, Korea, Republic of)</p>	<p>11:40 - 12:05</p>
<p><i>Data Blitz Session</i> 10:50 - 12:05</p>	
<p>S3</p>	
<p><b>Data Blitz 8: Schizophrenia treatment</b></p>	
<p><i>Chair:</i> Shyh-Yuh Wei (Tainan, Taiwan)</p>	
<p><b>Successful Antipsychotic Dose Tapering Leading to Better Cognition in Patients with Remitted Psychosis: A 2-year Prospective Randomized-Controlled Trial</b></p> <p><i>Speaker:</i> Chun-I Liu (Taipei, Taiwan)</p>	<p>10:50 - 10:56</p>
<p><b>Abnormalities of Subcortical Brain Volume throughout the Psychosis Course</b></p> <p><i>Speaker:</i> Yi-An Liao (Taipei, Taiwan)</p>	<p>10:56 - 11:02</p>
<p><b>Clinical Practice Recommendations for Switching to Longer-Interval Injectable Antipsychotics in Schizophrenia Patients: A Modified Delphi Study in China</b></p> <p><i>Speaker:</i> Wanyi Zhang (Beijing, China)</p>	<p>11:02 - 11:08</p>
<p><b>Design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled trial with evenamide, a glutamate modulator, add-on to SGA in patients with treatment-resistant schizophrenia</b></p> <p><i>Speaker:</i> Ravi Anand (St Moritz, Switzerland)</p>	<p>11:08 - 11:14</p>
<p><b>Effects of Semaglutide on Body Weight in Clozapine-Treated Individuals with Schizophrenia and Obesity: A Randomized Controlled Trial</b></p> <p><i>Speaker:</i> Dan Siskind (Brisbane, Australia)</p>	<p>11:14 - 11:20</p>
<p><b>Novel augmentation strategies for clozapine resistant schizophrenia: the role of adaptive platform trials</b></p> <p><i>Speaker:</i> Dan Siskind (Brisbane, Australia)</p>	<p>11:20 - 11:26</p>
<p><b>The benefits of clozapine beyond its antipsychotic properties in treatment-resistant schizophrenia</b></p> <p><i>Speaker:</i> Kannan Subramaniam (Auckland, New Zealand)</p>	<p>11:26 - 11:32</p>
<p><b>Impacts of Taiwan's National Health Insurance Dedicated Budget Policy on Long-Acting Injectable Usage: An Interrupted Time-Series Analysis</b></p> <p><i>Speaker:</i> Grace Hui-Min Wu (Taipei, Taiwan)</p>	<p>11:32 - 11:38</p>
<p><b>Exploring safe tapering of antipsychotics in patients with remitted psychosis: employing animal model and coadministration of N-Acetylcysteine study in bench and bedside</b></p> <p><i>Speaker:</i> Chen-Chung Liu (Taipei, Taiwan)</p>	<p>11:38 - 11:44</p>
<p><b>Discussion, Q&amp;A</b></p>	<p>11:44 - 12:05</p>

*Data Blitz Session*

10:50 - 12:05

M1

**CINP invited Biological Psychiatry Australia Data Blitz 1: Focus on Development, Cognition, Stress, Depression, and Fear**

*Chair:* Tertia Purves-Tyson (Sydney, Australia)

**Adversity-related changes to the spatial localisation of hippocampal cortisol receptors in psychiatric disorders** 10:50 - 10:56

*Speaker:* Amber Curry (Sydney, Australia)

**Endocannabinoids and intrusive memories: Evidence for a role of anandamide from two experimental human studies** 10:56 - 11:02

*Speaker:* Luke Ney (Brisbane, Australia)

**Prebiotics improve motor function, cognition and gut health in a preclinical model of Huntington's disease** 11:02 - 11:08

*Speaker:* Millicent Ekwudo (Melbourne, Australia)

**Linking Oestradiol (E2) Timing and Tempo, Brain Development, and Mental Health in Adolescent Females** 11:08 - 11:14

*Speaker:* Muskan Khetan (Melbourne, Australia)

**Temporal immune effects of oral ketamine on PTSD: transcriptomic evidence of short-term inflammation suppression and long-term immune remodelling** 11:14 - 11:20

*Speaker:* Nathan Wellington (Birtinya, Australia)

**Paternal immune activation via the viral mimic poly I:C leads to epigenetic changes in sperm and results in behavioural, brain and physiological changes in offspring** 11:20 - 11:26

*Speaker:* Nicholas Van de Garde (Melbourne, Australia)

**The impact of paternal cytokine administration on sperm small RNAs and offspring physiology and behaviour in mice** 11:26 - 11:32

*Speaker:* Pamudika Kiridena (Melbourne, Australia)

**Differential striatal gene expression profiles underlying the propensity for depression-like behaviour in a mouse model of vertical sleeve gastrectomy** 11:32 - 11:38

*Speaker:* Renee Papaluca (Melbourne, Australia)

**Baricitinib Reverses Depressive and Cognitive Deficits in a Rodent Model of Treatment-Resistant Depression** 11:38 - 11:44

*Speaker:* Roger Bitencourt Varela (Brisbane, Australia)

**Modelling cognitive and psychiatric behavioural traits in a mouse model of Neurofibromatosis type I** 11:44 - 11:50

*Speaker:* Sonali N. Reisinger (Melbourne, Australia)

**Whole brain activity mapping of the effects of a novel small molecule on chronic social isolation induced aggression in mice** 11:50 - 11:56

*Speaker:* Terry Salthouse (Sydney, Australia)

**The Effects of Maternal Immune Activation on the Phospho-Proteome of the Developing Adolescent Mouse Hippocampus** 11:56 - 12:02

*Speaker:* Ulysse Thivisol (Melbourne, Australia)

**Q&A, Discussion** 12:02 - 12:05

*Spotlight Session*

12:15 - 13:15

PL

**Spotlight Session 10: Treatment Resistant Depression (TRD): basic science and clinical reality**

*Chair:* Pierre Blier (Ottawa, Canada)

**Clinical reality of Treatment Resistant Depression (TRD)** 12:15 - 12:45

Speaker: Siegfried Kasper (Vienna, Austria)

**Basic Science of Treatment Resistant Depression (TRD)**

12:45 - 13:15

Speaker: Dan Rujescu (Wien, Austria)

Data Blitz Session

12:15 - 13:15

S1

**Data Blitz 9: OCD/behavioral**

Chair: Shih-Ku Lin (Taipei, Taiwan)

**Neural mechanisms of Brain-lymph nodes axis in stress-induced anxiety disorders**

12:15 - 12:21

Speaker: Dong Dong Shi (Shanghai, China)

**Pathological Networking of Gray Matter Dendritic Density With Classic Brain Morphometries in OCD**

12:21 - 12:27

Speaker: Qing Fan (Shanghai, China)

**Characterising the neuropeptide landscape of the postmortem human orbitofrontal cortex in health, following severe childhood adversity and in psychopathology**

12:27 - 12:33

Speaker: Katrina Z. Edmond (Sydney, Australia)

**Identifying specific EEG markers of Internet Gaming Disorder and the corresponding tDCS intervention: a randomized controlled double-blind study**

12:33 - 12:39

Speaker: Yixuan Song (Beijing, China)

**Changes in brain biochemical metabolites of cognitive flexibility impairment in non-medicated obsessive-compulsive disorder patients**

12:39 - 12:45

Speaker: Yanbin Jia (Guangzhou, China)

**Common and distinct neural substrates of cue craving response between substance and behavioral addiction: a neuroimaging meta-analysis**

12:45 - 12:51

Speaker: Qihong Zheng (Beijing, China)

**Role of orexin in reward-based decision-making strategies**

12:51 - 12:57

Speaker: Hiroyuki Mizoguchi (Nagoya, Japan)

**Correlation between trace elements and cognitive impairment in patients with first diagnosis of obsessive-compulsive disorder**

12:57 - 13:03

Speaker: Yiliang Zhang (Guangzhou, China)

**A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder**

13:03 - 13:09

Speaker: Bernard Lerer (Jerusalem, Israel)

**Discussion, Q&A**

13:09 - 13:15

Data Blitz Session

12:15 - 13:15

S2

**Data Blitz 10: Basic research-variable**

Chair: Lalit K. Srivastava (Montreal, Canada)

**Analysis of the effect of oxytocin analogues on a mouse contextual fear-conditioning behavior**

12:15 - 12:21

Speaker: Kento Igarashi (Kagoshima City, Japan)

**Cerebellar  $\alpha 6$ GABA<sub>A</sub> receptor as a potential therapeutic target for relieving core symptoms of autism: a preclinical study in prenatal valproic acid-exposure rats**

12:21 - 12:27

Speaker: Lih-Chu Chiou (Taipei, Taiwan)

<b>Agonism Heterogeneity: anti-amnesic SIGMAR1 agonists PRE-084 and (+)pentazocine differentially translocate SIGMAR1 to substructures of endoplasmic reticulum in Neuro2a cells</b>	12:27 - 12:33
<i>Speaker:</i> Yuko Yasui (Baltimore, United States)	
<b>High-speed treadmill running in young and old mice recorded with marker-based 3D motion capture</b>	12:33 - 12:39
<i>Speaker:</i> Bogna Ignatowska-Jankowska (Onna, Japan)	
<b>Paternal chronic bacterial-like infection induces intergenerational changes in offspring anxiety and cognition</b>	12:39 - 12:45
<i>Speaker:</i> Da Lu (Parkville, Australia)	
<b>Effects of Teneurin-4 knockdown in the prefrontal cortex on depressive behaviors in mice</b>	12:45 - 12:51
<i>Speaker:</i> Yusuke Yano (Toyama, Japan)	
<b>M4 muscarinic receptor activation in the central amygdala reduces stress-induced alcohol seeking in alcohol preferring rats</b>	12:51 - 12:57
<i>Speaker:</i> Roberta G Anversa (Melbourne, Australia)	
<b>Uncovering the role of GlyT2+ periaqueductal grey neurons in pain and pain-related behaviours</b>	12:57 - 12:57
<i>Speaker:</i> Caitlin Fenech (St Leonards, Australia)	
<b>Discussion, Q&amp;A</b>	12:57 - 13:15
 <i>Featured Communication</i>	
12:15 - 13:15	S3
<b>Featured Communication 7: Psychedelics related</b>	
<i>Chair:</i> Danilo De Gregorio (Milan, Italy)	
<b>Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration</b>	12:15 - 12:30
<i>Speaker:</i> Bernard Lerer (Jerusalem, Israel)	
<b>A long noncoding eRNA forms R-loops to shape emotional experience-induced behavioral adaptation</b>	12:30 - 12:45
<i>Speaker:</i> Makoto Taniguchi (Charleston, United States)	
<b>Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring</b>	12:45 - 13:00
<i>Speaker:</i> Cassandra Hatzipantelis (Davis, United States)	
<b>Discussion, Q&amp;A</b>	13:00 - 13:15
 <i>Selected Colloquium</i>	
12:15 - 13:15	M1
<b>Selected Colloquium 10: Promises and Pitfalls of Clinical Trial Design: How can we better evaluate novel target antipsychotics?</b>	
<i>Chair:</i> Anthony Grace (Pittsburgh, United States)	
<b>N-Acetyl-Cysteine (NAC) Intervention and Mitochondrial Mechanisms in- Early Psychosis Patients</b>	12:15 - 12:35
<i>Speaker:</i> Kim Q. Do (Lausanne, Switzerland)	
<b>Examining novel therapies within a clinical staging framework</b>	12:35 - 12:55
<i>Speaker:</i> Patrick McGorry (Parkville, Australia)	
<b>Preclinical studies of standard and novel target antipsychotic drugs in animal models of schizophrenia: Why clinical trials may have failed to recapitulate preclinical findings</b>	12:55 - 13:15
<i>Speaker:</i> Anthony Grace (Pittsburgh, United States)	

<i>Meet the Experts / Campfire Session</i>	
12:15 - 13:15	M2
<b>Meet the Expert 4: Schizophrenia (LIMITED SEATS)</b>	
<i>Chair:</i> Jimmy Lee (Singapore, Singapore)	
<b>Schizophrenia: Case Discussions</b>	12:15 - 13:15
<i>Speaker:</i> Dan Siskind (Brisbane, Australia)	
<i>Speaker:</i> Andrew Thompson (Australia)	
 <i>Break</i>	
13:15 - 14:40	SR
<b>Lunch Break</b>	
 <i>Sponsored Symposium</i>	
13:25 - 14:25	S1
<b>Sponsored Lunch Symposium</b>	
 <i>Symposium</i>	
14:40 - 15:55	PL
<b>Symposium 16: Muscarinic M1 and M4 receptors: Drug development, a treatment for schizophrenia and a potential treatment for addiction</b>	
<i>Chair:</i> Suresh Sundram (Clayton, Australia)	
<b>The development of drugs to activate the muscarinic M1 and M4 receptors to treat disorders of the human CNS</b>	14:40 - 15:05
<i>Speaker:</i> Carrie K. Jones (Nashville, United States)	
<b>Muscarinic receptors and the molecular pathology of schizophrenia</b>	15:05 - 15:30
<i>Speaker:</i> Brian Dean (Parkville, Australia)	
<b>Muscarinic M1 and M4 receptor stimulation reverse effects of cocaine across several assays</b>	15:30 - 15:55
<i>Speaker:</i> Morgan Thomsen (Copenhagen, Denmark)	
 <i>Symposium</i>	
14:40 - 15:55	S1
<b>Symposium 17: Connecting the Dots in Opioid Addiction: Brain Circuits, Stress, and Clinical Trials</b>	
<i>Chair:</i> Kazutaka Ikeda (Tokyo, Japan)	
<b>Targeting the ventral pallidum to treat opioid use disorder</b>	14:40 - 15:05
<i>Speaker:</i> Meaghan Creed (St. Louis, United States)	
<b>Understanding the impact of acute and chronic opioid exposure on endocannabinoid function and stress sensitivity in humans</b>	15:05 - 15:30
<i>Speaker:</i> Leah Mayo (Calgary, Canada)	
<b>Alleviating opioid withdrawal: from rodents to human clinical trial</b>	15:30 - 15:55
<i>Speaker:</i> Tuan Trang (Calgary, Canada)	
 <i>Symposium</i>	
14:40 - 15:55	S2
<b>Symposium 18: Neurodevelopmental Disorder Models and Mechanisms</b>	
<i>Chair:</i> Noriko Osumi (Sendai, Japan)	
<b>Deficiency of <i>Tbx1</i>, a gene encoded in 22q11.2 copy number variation, impairs social and cognitive behaviors by altering brain shape and neonatal stem cells</b>	14:40 - 15:05
<i>Speaker:</i> Noboru Hiroi (San Antonio, United States)	
<b>The role of NPAP1 ancestral and modern variants on circadian rhythms and lipid metabolism in Prader-Willi syndrome</b>	15:05 - 15:30

Speaker: Valter Tucci (Genova, Italy)

**Brain development in Fragile X syndrome: sex difference and parental epigenetic effect in the mouse model** 15:30 - 15:55

Speaker: Takako Kikkawa (Sendai, Japan)

Data Blitz Session

14:40 - 15:55

S3

**Data Blitz 11: Clinical research-variable**

Chair: Malcolm Hopwood (Melbourne, Australia)

**Clinical psychological predictors in process of formation gender asymmetries** 14:40 - 14:46

Speaker: Aleksandr Kim (Bishkek, Kyrgyzstan)

**Trihexyphenidyl Reduces Flashbacks in Patients with Posttraumatic Stress Disorder (PTSD)** 14:46 - 14:52

Speaker: Sogou Katsumasa (Hiroshima City, Japan)

**Exploration of the mechanism of action of massage interventions in human subjects** 14:52 - 14:58

Speaker: Mark Rapaport (Salt Lake City, United States)

**Prescription pattern and medical expenses in executive psychiatric clinic - RSUD Dr. Chasbullah Abdulmajid (Type B government hospital) Bekasi City Indonesia - period March - November 2024** 14:58 - 15:04

Speaker: Chrisna Mayangsari (Bekasi, Indonesia)

**Psilocybin and ketanserin vs rTMS in treatment-resistant depression: enhancing tolerability by mitigating psychedelic effects** 15:04 - 15:10

Speaker: Giovanni Martinotti (Chieti, Italy)

**Mental Health Australia General Clinical Trial Network (MAGNET) - connecting knowledge for better mental health outcomes** 15:10 - 15:16

Speaker: Michael Berk (Geelong, Australia)

**L-methylfolate: from novel agent to mainstream psychiatric practice** 15:16 - 15:22

Speaker: Vivienne Mak (Melbourne, Australia)

**Collecting and evaluating animal models in mental health science and building an online resource for researchers: a Wellcome initiative** 15:22 - 15:28

Speaker: Rachel Hill (Clayton, Australia)

**Discussion, Q&A** 15:28 - 15:55

Data Blitz Session

14:40 - 15:55

M1

**CINP invited Biological Psychiatry Australia Data Blitz 2: Focus on Schizophrenia and Psychosis**

Chair: Ariel Dunn (Melbourne, Australia)

**Investigating cellular phenotypes and genotypes of a preclinical model relevant to schizophrenia using single-cell RNA sequencing** 14:40 - 14:45

Speaker: Angel Yonehara (Melbourne, Australia)

**Iron dyshomeostasis is linked to downregulated amyloid precursor protein in schizophrenia prefrontal cortex: a postmortem study** 14:45 - 14:50

Speaker: Carlos M Opazo (Melbourne, Australia)

**Cholinergic muscarinic type 4 receptor dominates Xanomeline's efficacy, with essential contribution from type 1 receptor** 14:50 - 14:55

Speaker: Christopher Choy (Melbourne, Australia)

<p><b>Sex-dependent and dynamic brain structural MRI changes in mice following influenza A virus maternal immune activation</b></p> <p><i>Speaker:</i> Danli Peng (Melbourne, Australia)</p>	<p>14:55 - 15:00</p>
<p><b>Dissecting Epigenetic Heterogeneity in Schizophrenia</b></p> <p><i>Speaker:</i> Dylan Kiltschewskij (Newcastle, Australia)</p>	<p>15:00 - 15:05</p>
<p><b>Schizophrenia-like endophenotypes in Amyloid Precursor Protein knock out mice</b></p> <p><i>Speaker:</i> Jackson Choong (Melbourne, Australia)</p>	<p>15:05 - 15:10</p>
<p><b>Patient-derived microglia-containing organoids for investigating neuroanatomical phenotypes in schizophrenia</b></p> <p><i>Speaker:</i> Jordan Clarke (Melbourne, Australia)</p>	<p>15:10 - 15:15</p>
<p><b>Relationship between electroencephalography-based mismatch negativity and antipsychotic treatment response in young people at clinical high risk for psychosis</b></p> <p><i>Speaker:</i> Magdalene de Rozario (Melbourne, Australia)</p>	<p>15:15 - 15:20</p>
<p><b>Serum iron abnormalities in Treatment resistant Schizophrenia are not observed in Frontotemporal dementia</b></p> <p><i>Speaker:</i> Naimisha Talluri (Melbourne, Australia)</p>	<p>15:20 - 15:25</p>
<p><b>Serum elements and oxidative stress indices are altered in treatment-resistant schizophrenia</b></p> <p><i>Speaker:</i> Sandra Luza (Melbourne, Australia)</p>	<p>15:25 - 15:30</p>
<p><b>Maternal immune activation and estrogen receptor modulation induce sex-specific dopamine-related behavioural and molecular alterations in adult rat offspring</b></p> <p><i>Speaker:</i> Sophie Debs (Sydney, Australia)</p>	<p>15:30 - 15:35</p>
<p><b>Are psychiatric diagnoses associated with a robust neuroanatomical phenotype? An assessment of the reproducibility of grey matter differences in mental illness</b></p> <p><i>Speaker:</i> Trang Cao (Clayton, Australia)</p>	<p>15:35 - 15:40</p>
<p><b>Using large-scale genetic studies to find drug targets in schizophrenia: where are we at?</b></p> <p><i>Speaker:</i> William Reay (Hobart, Australia)</p>	<p>15:40 - 15:45</p>
<p><b>Discussion, Q&amp;A</b></p>	<p>15:45 - 15:55</p>
<p><i>Break</i> 15:55 - 16:35</p> <p><b>Afternoon Coffee Break</b></p>	<p>SR</p>
<p><i>Featured Communication</i> 16:35 - 17:35</p> <p><b>Featured Communication 8: Cognition related</b></p> <p><i>Chair:</i> Noriko Osumi (Sendai, Japan)</p>	<p>PL</p>
<p><b>Selective potentiation of <math>\alpha 5</math>-GABAA receptors contributes to reduction of cognitive burden and neuronal loss in aging mice - **Rafaelsen Young Investigators Award 2025**</b></p> <p><i>Speaker:</i> Thomas Prevot (Toronto, Canada)</p>	<p>16:35 - 16:50</p>
<p><b>Mechanisms and pharmacological therapy of intergenerational neurocognitive deficiencies induced by exposure to the general anesthetic sevoflurane</b></p> <p><i>Speaker:</i> Anatoly Martynyuk (Gainesville, United States)</p>	<p>16:50 - 17:05</p>
<p><b>Sensors in-home for elder wellbeing (SINEW): digital phenotyping</b></p>	<p>17:05 - 17:20</p>

**and artificial intelligence for early detection of dementia**

Speaker: Iris Rawtaer (Singapore, Singapore)

**The effectiveness of vagus nerve stimulation in the treatment of alzheimer's and parkinson's disease: a systematic review**

17:20 - 17:35

Speaker: Ruihua Hou (Southampton, United Kingdom)

*Featured Communication*

16:35 - 17:35

S1

**Featured Communication 9: Variable**

Chair: Lucie Bartova (Vienna, Austria)

**Microglia integrates multiple stress signals via distinct molecular pathways for behavioral dysfunctions**

16:35 - 16:50

Speaker: Tomoyuki Furuyashiki (Kobe, Japan)

**Predicting intermittent TBS treatment response in patients with major depressive disorder using concurrent TBS/fNIRS and machine learning**

16:50 - 17:05

Speaker: Rebecca Kan (Hong Kong, China)

**A Study on Co-Administration of Metformin along with Olanzapine on Changes in Body Weight, Waist Circumference, Fasting Blood Sugar and Lipid Profile in schizophrenia**

17:05 - 17:20

Speaker: Gautam Saha (Kolkata, India)

**Evenamide, a glutamate modulator, provided statistically significant benefits when added to SGA in patients with schizophrenia: phase 2/3, international, randomized, double-blind, placebo-controlled study results**

17:20 - 17:35

Speaker: Ravi Anand (St Moritz, Switzerland)

*Featured Communication*

16:35 - 17:35

S2

**Featured Communication 10: Schizophrenia/Variable**

Chair: Suresh Sundram (Clayton, Australia)

**Converging human-specific evidence implicates astrocytic glutamate regulation in stress-related psychiatric disorders**

16:35 - 16:50

Speaker: Natalie Matosin (Sydney, Australia)

**Epitranscriptomic regulation of striatal function: a new neurobiology of schizophrenia?**

16:50 - 17:05

Speaker: Xiaoying Cui (Brisbane, Australia)

**Longitudinal cortical thickness changes in first episode psychosis: a triple-blind randomised placebo-controlled MRI study**

17:05 - 17:20

Speaker: Sidhant Chopra (Melbourne, Australia)

**Microglia/Macrophage transcripts are increased in neuroinflammatory schizophrenia and bipolar disorder midbrains**

17:20 - 17:35

Speaker: Gerardo Mendez-Victoriano (Sydney, Australia)

*Featured Communication*

16:35 - 17:35

S3

**Featured Communication 11: Depression/Variable**

Chair: Nasser Haddjeri (Bron, France)

**Linking prenatal inflammation to synaptic dysfunction in psychiatric disorders**

16:35 - 16:50

Speaker: Jose Agustin Cota Coronado (Melbourne, Australia)

**Efficacy of lumateperone 42 mg in the treatment of major**

16:50 - 17:05

<b>depressive disorder: a pooled analysis of phase 3 randomized controlled trials</b>		
<i>Speaker:</i> Suresh Durgam (Bedminster, United States)		
	<b>Identification of blood biomarkers of psilocybin-assisted therapy treatment response for generalised anxiety disorder</b>	17:05 - 17:20
<i>Speaker:</i> Andrew Gibbons (Clayton, Australia)		
	<b>Long-term adjunctive lumateperone treatment in major depressive disorder: results from a six-month open-label extension study</b>	17:20 - 17:35
<i>Speaker:</i> Willie Earley (Bedminster, United States)		
 <i>Data Blitz Session</i>		
16:35 - 17:35		M1
<b>CINP invited Biological Psychiatry Australia Data Blitz 3: Focus on Addition and Eating Disorders</b>		
<i>Chair:</i> Leigh Walker (Melbourne, Australia)		
	<b>Exploring the potential of gut taste receptors for the treatment of disordered eating behaviour</b>	16:35 - 16:41
<i>Speaker:</i> Caiwei lin (Melbourne, Australia)		
	<b>Uncovering multiday patterns in regulatory control: A personalized framework for capturing longer-term patterns in self-regulation</b>	16:41 - 16:47
<i>Speaker:</i> Jodie Naim-Feil (Melbourne, Australia)		
	<b>Estrous cycle-dependent effects of a tropomyosin receptor kinase B agonist on fear extinction in female adolescent rats</b>	16:47 - 16:53
<i>Speaker:</i> Kathryn Baker (Melbourne, Australia)		
	<b>Insights into the post-acute effects of psilocybin on reward-driven dopaminergic responses during probabilistic reversal learning in female rats</b>	16:53 - 16:59
<i>Speaker:</i> Kyna Conn (Clayton, Australia)		
	<b>Assessing the utility of zuranolone to modify alcohol-related behaviours</b>	16:59 - 17:05
<i>Speaker:</i> Lauren Ursich (Melbourne, Australia)		
	<b>Investigating the role of orexin in stress-induced binge eating in female mice</b>	17:05 - 17:11
<i>Speaker:</i> Mia Jessica O'Shea (Melbourne, Australia)		
	<b>Investigating the potential of psilocybin for compulsive eating in a rat model of binge eating</b>	17:11 - 17:17
<i>Speaker:</i> Nicolo Fabila (Melbourne, Australia)		
	<b>Feasibility and preliminary efficacy of N-Acetylcysteine for loss of control eating: an open label study</b>	17:17 - 17:23
<i>Speaker:</i> Robyn Brown (Parkville, Australia)		
	<b>Ghrelin receptor signalling in the Edinger-Westphal nucleus regulates binge drinking in a sex-specific manner</b>	17:23 - 17:29
<i>Speaker:</i> Xavier Maddern (Melbourne, Australia)		
	<b>Discussion, Q&amp;A</b>	17:29 - 17:35
 <i>Plenary</i>		
17:40 - 18:25		PL
<b>Closing Ceremony</b>		